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Spondyloarthritis (SpA) comprises a heterogeneous group of distinct disorders including ankylosing 
spondylitis (AS), non-radiographic axial SpA, psoriatic arthritis, arthritis related to inflammatory 
bowel disease and reactive arthritis1.  SpA is the second most prevalent form of chronic 
inflammatory arthritis, with an estimated prevalence of about 0.5-1.5%2. This condition is 
characterized by inflammation as well as structural damage3. The inflammatory process affects the 
axial skeleton and the sacroiliac joints (SI), the peripheral joints and may extend to organs such as 
eye, skin and gut.    
 
Clinical presentation 
The disease SpA usually starts in the second or third decade of life and has a male predominance. 
The clinical picture includes chronic back pain, peripheral arthritis, enthesitis and extra-articular 
manifestations such as uveitis, psoriasis and inflammatory bowel disease (IBD)4. Patients present 
with chronic back pain and morning stiffness of the lower back, but any part of the spine can be 
involved. Inflammatory back pain (IBP) is typical. IBP has been clinically defined and different sets 
of criteria have been developed5. Arthritis and enthesitis are the most common peripheral 
manifestations that can occur at any time in the course of the disease. The joints may be swollen 
and/or painful and the lower limbs are most often affected, frequently in an asymmetrical fashion.  
 
Comorbidities and risk factors 
Comorbidities are frequently associated with inflammatory rheumatic diseases including SpA. In 
addition to the musculoskeletal manifestations for SpA and SpA-related extra-articular features, 
patients may also have an increased risk of cardiovascular events, arterial hypertension, metabolic 
syndrome, malignancies and infections6. An optimal detection and monitoring of comorbidities and 
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risk factors may have implications not only for treatment planning but also for the prevention of 
these conditions in daily clinical practice.   
 
Classification criteria 
As for every rheumatological disease, diagnostic criteria for SpA are lacking. Different sets of 
criteria have been proposed for the classification of SpA (that means: to be applied in patients with 
a diagnosis of SpA). According to the modified New York criteria, the presence of radiographic 
sacroiliitis (grade 2 bilateral or grade 3-4 unilaterally) in combination with one of the clinical criteria 
(low back pain or limitation of the lumbar spine or limitation of chest expansion), is mandatory in 
order to classify a patient as having AS7. The European Spondylarthropathy Study Group (ESSG)-
criteria 8 and the Amor-criteria9 were the first aiming at classifying patients along the whole disease 
spectrum. The entry-criterion of the ESSG criteria is the presence of IBP or peripheral arthritis. 
Patients with one of these entry criteria in combination with one minor criterion are classified as 
SpA according to the ESSG criteria. In contrast, in the Amor criteria a list of signs are included and 
none of them is required for classifying a patient as having SpA. In 2009 ASAS has proposed two 
classification criteria sets for SpA. One set can be applied in patients that have presented with 
predominantly axial involvement (axSpA)10, and the other set can be applied in patients that have 
presented with predominantly peripheral involvement (pSpA)11.  The axSpA-criteria can be applied 
in patients that have presented with chronic back pain (≥3 months) starting before the age of 45 
years. This set consist of two arms: the imaging arm and the clinical arm. Patients can be classified 
in the imaging arm when one SpA-feature is present in addition to sacroiliitis on radiographs or 
magnetic resonance imaging (MRI).  Patients can be classified according to the clinical arm if two 
SpA features are present in addition to HLA-B27 positivity. The pSpA criteria can be applied in 
patients that have presented with at least one of the peripheral manifestations arthritis, enthesitis 
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or dactylitis. A patient with peripheral manifestations can fulfil pSpA criteria if at least one of the 
following SpA feature is present in addition: uveitis, psoriasis, IBD, preceding infection, HLA-B27 
positivity or sacroiliitis on imaging; or if at least two of the following additional SpA features are 
present: arthritis, enthesitis, dactylitis, IBP or a positive family history for SpA.  
 
The ASAS/OMERACT core set 
In an attempt to bring homogeneity in outcome assessment in AS, the Assessment of 
SpondyloArthritis international Society (ASAS) has selected a core set of variables that have been 
endorsed by the Outcome Measures in Rheumatology Clinical Trials (OMERACT) group. This core 
set is intended to be used as standardised end-points in clinical trials and in clinical practice. Three 
scenarios for core sets have been defined: (1) disease controlling anti-rheumatic therapy (DC-ART), 
(2) symptom modifying anti-rheumatic drugs (SMARDs) and physical therapy and (3) clinical record 
keeping. The domains selected for all three core sets include ‘physical function’, ‘pain’, ‘spinal 
mobility’, ‘spinal stiffness’, ‘fatigue’ and ‘patient’s global assessment’. The DC-ART core sets and 
clinical record keeping further include ‘peripheral joints/entheses’ and ‘acute phase reactants’, and 
the core set for DC-ART includes ‘radiographs of the spine’. Specific instruments to assess the 













Table ASAS/OMERACT core set for SMARD, DC-ART and specific instruments  
Domains Instruments 
Function BASFI 
Pain NRS/VAS (last week/spine/night/due to AS) 
NRS/VAS (last week/spine/due to AS) 
Spinal mobility Chest expansion, modified Schober, occiput to wall, cervical 
rotation, (lateral spinal flexion or BASMI) 
Spinal stiffness NRS/VAS (duration of morning stiffness, spine, last week) 
Patient global NRS/VAS (global disease activity last week) 
Peripheral joint, entheses Number of swollen joints (44 joint count) MASES, 
San Francisco or Berlin 
Acute phase reactants CRP or ESR 
Radiograph spine mSASSS on lateral lumbar spine / lateral cervical spine 
Fatigue Fatigue question BASDAI 
ASAS, Assessment of SpondyloArthritis international Society; OMERACT, Outcome Measures in 
Rheumatology Clinical Trials; DC-ART, disease controlling anti-rheumatic therapy; SMARD, 
symptom modifying anti-rheumatic drugs; BASDAI, Bath Ankylosing Spondylitis Functional Index; 
NRS, Numerical Rating Scale; VAS, Visual Analogue Scale; BASMI, Bath Ankylosing Spondylitis 
Metrology Index; MASES, Maastricht Ankylosing Spondylitis Enthesis Score; CRP, C-reactive 
protein; ESR, Erythrocyte Sedimentation Rate; mSASSS, modified Stoke Ankylosing Spondylitis 
Spinal Score; BASRI, Bath Ankylosing Spondylitis Radiology Index; BASDAI, Bath Ankylosing 
Spondylitis Disease Activity Index 
 
 
Clinical assessment and monitoring 
Assessment and monitoring is important in systemic diseases that may present with a variety of 
symptoms and signs, such as SpA. Each of these symptoms can be assessed in clinical practice using 
different instruments. Disease monitoring should include patient history (patient oriented 
questionnaires), clinical parameters including spinal mobility, laboratory tests and imaging, all 
according to clinical presentation, as well as the ASAS core set12. In this regard, instruments for the 
assessment and monitoring of the disease have been validated for use in clinical practice as well as 
in clinical trials13. Disease activity indices are relevant for monitoring disease activity in patients 
with SpA. The Bath AS Disease Activity Index (BASDAI) and recently the AS Disease Activity Score 
(ASDAS) are the most important indices available for clinical practice. The ASDAS-CRP is 
recommended by ASAS and validated cut-off levels for levels of disease activity as well as 




Health and functioning assessment 
General health and functioning are of pivotal importance when assessing the impact of the disease 
on the patient.  Recently, the ASAS Health Index (HI) has been developed to measure functioning 
and health in patients with SpA aiming to better describe the impact of disease in these patients15. 
The ASAS-HI is a new and linear composite measure based on an item pool which has been 
developed and based on the International Classification of Functioning core set for AS. This 
composite index forms a unidimensional scale providing a sum score representing a wide spectrum 
of different levels of functioning, and it contains 17 dichotomous questions addressing the 
following categories: pain, emotional functions, sleep, sexual functions, mobility, self-care, 
community life and employment.  
 
Magnetic Resonance Imaging and HLA-B27 
In addition to the clinical picture, imaging (radiography and magnetic resonance imaging (MRI)) 
and laboratory data (HLA-B27 and C-reactive protein (CRP)) are important tools in daily clinical 
practice when assessing patients with SpA. MRI of the sacroiliac (SI) joints has become an important 
tool in the diagnosis and classification of SpA and its introduction as a diagnostic test has been a 
major advance in the field of SpA. MRI is particularly important for early diagnosis, especially 
because if its sensitivity to active inflammatory lesions early in the course of the disease, and often 
well before definite lesions on conventional radiographs are detectable16. This makes MRI the most 
sensitive imaging modality available for the detection of sacroiliitis. The role of HLA-B27 in the 
diagnosis, prognosis and management of SpA has been extensively investigated. HLA-B27 has been 
associated with an increased severity and persistence of SI-MRI- inflammation in (especially male) 
patients with IBP17. SI-MRI as well as HLA-B27 help to secure a diagnosis of axSpA and both have a 
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high specificity18. In addition to sacroiliitis on radiographs, SI-MRI as well as HLAB27 serve as entry 
criteria in the ASAS classification criteria for axSpA. Additionally both tests (sacroiliitis by MRI and 
HLA-B27 positivity) have been included in the decision tree of the original and modified Berlin 
diagnostic algorithm and can be applied in clinical practice19.  
 
Current situation regarding SpA in Colombia 
Data in the literature reporting the behaviour of SpA in Colombia is limited and many efforts have 
been made to describe the landscape of this condition in the country. Just as in other countries in 
Latin America, research about SpA is far less mature than research about other rheumatic disorders 
such as rheumatoid arthritis (RA) and systemic lupus erythematous20. The research in the field of 
SpA performed in Colombia has been rather descriptive and based on clinical cohorts of patients 
in academic centers reporting disease manifestations, prognostic factors, biomarker levels and 
frequencies of HLA-B27.   
 
Information from many studies performed in Colombia provide a preliminary impression with 
regard to clinical presentation, main features and frequency of subtypes. One of the first analyses 
was the characterization, description of features by subtypes and the follow-up of 139 patients 
with SpA21. Male gender, the presence of uveitis and the early age of disease onset were associated 
with a worse prognosis (more disease progression) of AS patients.  In another study, increasing 
serum levels of biomarkers (IL-17, IL-23, IL-6, TNF-α, IL-1 α and CRP) were shown to be associated 
with poorer prognosis of patients with SpA22. Similarly, positive associations between enthesitis 
and IL-17 serum levels and between enthesitis and IL-23 synovial fluid levels were found in a small 




Higher frequencies of peripheral involvement have been consistently observed in Latin America. In 
a cohort of Colombian patients, peripheral oligo-arthritis has been reported in a range of 65% to 
76% and enthesitis in a range of 67% to 86%24. These findings are similar to those reported in 
Mexico and Brazil: they found arthritis in 66% and enthesitis in 54% of the patients25. A rather low 
frequency of HLA-B27 positivity has been observed in SpA patients (about 40-45%)26, in contrast to 
data reported in Europe. Differences in the prevalence of HLA-B27 in the general population, which 
has a wide geographic and ethnic variation (≥75% of population in Colombia is mestizo27), may 
explain these discrepancies.  
 
Colombia faces many challenges with regard to the research in the field of SpA. The estimated total 
population at 2016 was more than 48 million as reported by the National Administrative 
Department of Statistics (DANE). The National Rheumatology Association (Asoreuma) in Colombia 
reports 160 rheumatologist working in 18 cities across the country especially in large cities. This 
means that Colombia has a rate of one rheumatologist per 302.000 inhabitants, which is three 
times below the optimal provision of rheumatology health-care requirements as estimated by the 
British Society of Rheumatology28.  
 
Numerically, the current workforce is insufficient to provide appropriate rheumatology care and 
workforce is critical in order to focus better on specific diseases such as SpA. This situation is similar 
to that in other countries of the continent, even though the rheumatology workforce has improved 
in LA during the last years29. Currently, five universities in Colombia provide training in 





Outline of this thesis 
In general terms, the objectives of this thesis were:   
1. To assess the performance of SpA classification criteria in SpA patients from Colombia and to 
investigate the current use of diagnostics tests in clinical practice in Colombia. 
2. To investigate the prevalence of comorbidities in SpA patients in Colombia and to explore if SpA 
is –like other rheumatological conditions - associated with periodontitis. 
3. To describe the validation and language translation of the ASAS-HI in patients with SpA in 
Colombia.   
4. To evaluate the implementation of the ASAS/OMERACT core set for axial SpA in world-wide 
clinical trials. 
The new ASAS classification criteria have been applied in different clinical settings especially in 
Europe. However, the ASAS criteria had not yet been applied and tested in a South American 
population.  Therefore, in chapter 2 a description of the performance of the ASAS classification 
criteria in a Colombian cohort of patients with SpA is presented and analysed in comparison to 
other criteria sets. SI-MRI and HLA-B27 are widely used in the diagnosis of axSpA and have a 
prominent place in the ASAS classification criteria, not only as an entry criterion but also as a 
related SpA feature. The relevance of both tests as central parameters in defining the spectrum of 
SpA as a whole (classification) is clear. However, these test are rather costly and waiting time for 
MRI is long in many countries, which jeopardises widespread use for diagnostic purposes in many 
countries among which Colombia. Many have suggested to preselect patients in the diagnostic 
work-up of SpA so that some unnecessary expenses for MRI/HLAB27 testing can be avoided. In 
chapter 3 we investigate the patient’s characteristics associated with the decision of the 




An increased prevalence of several comorbidities has been reported in SpA patients; the risk of 
developing such comorbid conditions seems to be higher in patients with SpA than in the general 
population. But data about such comorbid conditions in SpA patients from Latin America are 
scarce.  In chapter 4 comorbidities and risk factors in SpA-patients from Latin America have been 
investigated. A comparative analysis with the general population was performed using data from 
the multinational ASAS-COMOSPA study.  
 
SpA is a condition that is characterized by inflammatory features and extra articular manifestations. 
Previous studies, particularly in RA, have pointed towards a relationship between periodontitis (a 
chronic inflammatory condition characterized by loss of the periodontal ligament and alveolar 
bone) and systemic rheumatic diseases30. But it is unclear whether SpA patients also have a higher 
frequency of periodontitis and data in the literature reporting a possible association is limited.  
Therefore, in chapter 5 we investigate and compare the frequency of periodontitis in SpA patients 
with that in healthy individuals from the population.  
 
The overall picture of impairments, limitations, and restrictions in activities or social participation 
of patients with SpA has been aggregated in the composite ASAS Health Index31 This index captures 
the whole range of functioning and disability of patients with SpA. In order to make such an index 
performing properly, a thorough adaptation from English into Spanish (spoken in Colombia) is of 
pivotal importance. In chapter 6 the description of the translation and cross-culturally adaptation 
of the English version of the ASAS-HI into Spanish-language spoken in Colombia is presented. 
 
The ASAS/OMERACT core outcome set has importantly facilitated the development and successful 
regulatory approval of new treatments in AS. However, thus far the true implementation of the 
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core sets has not yet been evaluated. In chapter 7 we report the results of a systematic literature 
review aiming at analysing and comparing the usage of domains and instruments of the core sets 
before vs. after the original publication of the core set in randomized clinical trials.  
 
Chapter 8 consists of a summary and a general discussion of the findings presented in this thesis. 
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Objective: To investigate the performance of classification criteria sets (ASAS, ESSG, and Amor) for 
spondyloarthritis (SpA) in a clinical practice cohort in Colombia, and provide insight into how 
rheumatologists follow the diagnostic path in patients suspected of SpA.  
Methods: Patients with a rheumatologist’s diagnosis of SpA were retrospectively classified 
according to three criteria sets. Classification rate was defined as the proportion of patients fulfilling 
a particular criterion. Characteristics of patients fulfilling and not fulfilling each criteria were 
compared.  
Results: The ASAS criteria classified 81% of all patients (n=581) as having either axial-SpA (44%) or 
peripheral-SpA (37%), whereas a lower proportion met ESSG-criteria (74%) and Amor-criteria 
(53%). There was a high degree of overlap among the different criteria, and 42% of the patients 
met all three criteria. Patients fulfilling all three criteria sets were older (36 vs. 30 years), had more 
SpA-features (3 vs. 1 features) and more frequently had a current or past history of back pain (77% 
vs. 43%), inflammatory back pain (47% vs. 13%), enthesitis (67% vs. 26%) and buttock pain (37% vs. 
13%) vs those not fulfilling any criteria. HLA-B27, radiographs and MRI-SI were performed in 77%, 
59% and 24% of the patients respectively. 
Conclusion: The ASAS criteria classified more patients as having SpA in this Colombian cohort when 
the rheumatologist’s diagnosis is used as an external standard. Although physicians do not perform 
HLA-B27 or imaging in all patients, they do require these tests if the clinical symptoms fall short of 








Spondyloarthritis (SpA) comprises a heterogeneous group of diseases that share common clinical, 
radiological and genetic characteristics. SpA includes among others ankylosing spondylitis (AS), 
undifferentiated SpA (uSpA), reactive arthritis (ReA), psoriatic arthritis (PsA) and SpA associated 
with inflammatory bowel disease (IBD) 1. Several sets of classification criteria have been developed 
for clinical and epidemiological studies. The European Spondylarthropathy Study Group (ESSG) 2 
and the Amor 3 were the first criteria aimed at classifying patients along the whole disease 
spectrum. However, these two criteria sets do not perform as well in early recognition of the 
disease 4 5 and do not distinguish between axial and peripheral disease in separate sets6. Recently, 
the Assessment of SpondyloArthritis international Society (ASAS) criteria were developed for the 
classification of patients with SpA and for better distinguishing between patients with axial-SpA 
(axSpA) 7 and peripheral-SpA (pSpA) 8. 
 
Diagnostic criteria for SpA are lacking but diagnostic algorithms have been developed. The 
adaptation of the ‘Berlin algorithm’, might be a useful tool in clinical practice 9. In clinical setting, a 
flexible approach is often applied: complete clinical data are rarely obtained, important clinical 
questions could be missed, and the rheumatologist, rather than a fixed protocol, determines 
whether additional clinical testing (imaging, HLA-B27) is necessary. Consequently, applying 
classification criteria including such “on request only” tests may suffer from many missing data and 
yield different results in clinical practice than in validation cohorts. 
 
The ASAS-SpA criteria 6,7 were recently applied in different clinical settings. The full criteria were 
tested in a cohort with long-standing SpA 10, and the pSpA criteria were tested in a particular cohort 
of patients with recent-onset arthritis 11, both European cohorts. However, to our knowledge the 
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ASAS-criteria have not been applied in a South-American population. By default, classification 
criteria in clinical practice should be applied to patients that have been diagnosed by the 
rheumatologist; they are not diagnostic criteria. Consequently, they should be tested against the 
clinical judgment of the rheumatologist. Because of the nature of classification criteria, it can be 
expected that sensitivity is relatively low, but if performing well, specificity should be high 5.  
 
The main objectives of this study are twofold: first, to test how the ASAS-criteria perform in the 
context of the clinical Colombian rheumatology setting in comparison to other criteria sets. Second, 
to provide a general insight about how rheumatologists follow the diagnostic path in a patient 
suspected of having SpA. The cohort was established before the development and implementation 
of ASAS-criteria; therefore, the participating rheumatologists were unlikely to be biased with 




Consecutive patients were included between January-2002 and June-2010 in a single-centre study 
of patients referred to a specialised rheumatology outpatient clinic in a national referral centre. 
Patients with a clinical diagnosis of SpA (defined as the “reference standard”) by one of two 
rheumatologists who were considered experts in the field (RV and JL), were selected and included 
in the study on the first visit to the clinic. The inclusion of the patients was based on the clinical 
diagnosis and not on any set of classification criteria.  Then, this cohort of patients based on SpA 
clinical diagnoses by the rheumatologist, was further analysed for the characteristics included in 
the ASAS, ESSG and Amor-criteria. Patient information was based on the information from the 
clinical record. The institutional ethics committee approved this study, which was conducted under 
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the principles of Helsinki declaration. Patients signed informed consent to collect, file and use the 
data. 
 
Demographic, clinical and imaging characteristics 
The following information was included in the database: patient demographics, spinal mobility 
measures (occiput to wall distance, chest expansion, modified Schober test, lateral spinal flexion), 
laboratory tests [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and HLA-B27 
testing]; age at assessment, age at first symptoms, symptom duration, family history of SpA and the 
history (past) and presence (current) of chronic back pain (more than 3 months), inflammatory back 
pain, alternating buttock pain, asymmetric oligoarthritis (predominantly in lower limbs), enthesitis 
(heel pain), dactylitis (“sausage-shape” digit), uveitis (confirmed by ophthalmologist) and psoriasis. 
Functional capacity and disease activity were measured by the BASFI 12 and BASDAI13, respectively. 
The Ankylosing Spondylitis Disease Activity Score (ASDAS), was also calculated: ASDAS-ESR and 
ASDAS-CRP14. Acute phase reactants, HLA-B27, and the results of plain radiographs and MRI of 
sacroiliac joints (SI) were retrieved from the clinical file, as requested by rheumatologist. All data 
was collected at the initial visit to the clinic. Data related to follow-up were not included. 
 
The rheumatologist interpreted the radiographs according to the modified New York classification 
for radiographic sacroiliitis 15. Sacroiliitis on MRI was defined according to the local experienced 
musculoskeletal radiologist’s interpretation of the presence of active inflammatory changes in the 
SI-joint 16. This is according usual clinical practice (no central reading was done). The 
rheumatologists assessed the patients in the clinic and provided the clinical diagnosis of SpA 
categorized by subtypes: AS, uSpA, ReA, PsA and IBD. It was recorded in the clinical file and used as 
the external standard to test against.  
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Criteria for classification 
Retrospectively each patient who had a clinical diagnosis of SpA was classified according to ASAS 
axial and peripheral SpA, ESSG and Amor-criteria. If the presenting symptom was ‘back pain’, 
patients were classified according to the axSpA-criteria. If the presenting symptom was ‘arthritis, 
enthesitis and/or dactylitis’, patients were classified according to the pSpA-criteria (also if they 
reported back pain in the past). The ESSG and Amor-criteria were applied using radiographs for the 
imaging criterion. In these criteria (ESSG and Amor), when the patient had MRI findings of 
“sacroiliitis on MRI” (active inflammatory changes), this finding was used as a substitute for 
radiographic damage into the original criteria to fulfill the imaging criterion.  If information on a SpA 
feature or a test was not available, it was considered absent. 
 
Data analyses 
Disease characteristics were analysed using descriptive statistics, such as mean (SD) for continuous 
variables and percentages for categorical variables. The classification rate was defined as the 
proportion of patients fulfilling a particular criterion (numerator) and the total number of patients 
in the cohort (denominator). The concordance between the different criteria sets was analysed 
representing the proportion of patients who were also captured by another criterion. Venn-
diagrams were constructed representing patients who met one or more of the ASAS, ESSG, and 
Amor-criteria sets. In addition, we present patients with overlap between clinical diagnosis and 
fulfillment in the axial and peripheral ASAS-criteria in a Venn-diagram. Disease characteristics of 
patients fulfilling each classification criteria set vs. those who did not, were compared by t-test for 
continuous variables and by Chi-Square test for categorical variables. All analyses were performed 






The population consisted of 581 patients. Table-1 presents the descriptive characteristics of the 
cohort in total and split by disease subtype, according to clinical diagnosis (external standard). 
Overall, 72% of patients were men with mean (SD) age of 35 (13.5) years, symptom duration of 7.3 
(9.7) years and age at the beginning of the symptoms of 28 (10.3) years. In total, 76% of patients 
had a history of -or had current- chronic back pain, and 64% of these had IBP. Seventy-two percent 
had a history of -or had current- asymmetric oligo-arthritis, and 57% had a history of -or had 
current- enthesitis. Disease activity was calculated separately for patients with axial or peripheral 
SpA. Axial-SpA patients had a mean (SD) BASDAI of 5.4 (2.4) an ASDAS-CRP of 2.6 (0.8) and an 
ASDAS-ESR of 3.0 (0.9). Peripheral-SpA patients had a BASDAI of 5.3 (2.5), an ASDAS-CRP of 2.3 (0.9) 














Table 1. Descriptive characteristics of the patients according to the rheumatologist’s 


















       
















































       
Chronic back pain, 












































































































































































































       
Values are given as the means (SD) for the continuous variables and as a percentage for the categorical 
variables, unless otherwise specified.  
* refers to a history (past) or the presence (current) of these features at the time of assessment 
AS, ankylosing spondylitis; uSpA, undifferentiated spondyloarthritis; ReA, reactive arthritis; PsA, 
psoriatic arthritis; IBD, SpA associated with inflammatory bowel disease; CRP, C-reactive protein; 
ESR, erythrocyte sedimentation rate; MRI, magnetic resonance imaging; IBP, inflammatory back pain; 






Imaging and lab characteristics 
HLA-B27 testing was performed in 77% of the patients and 43.9% of them were positive. Regarding 
imaging, radiographs and MRI-SI were performed in 59% and 24% of the patients respectively. 
Splitting by disease subtype, the subgroup of patients in which most information was available was 
the subgroup of AS: radiographs: 92%; MRI: 26%; and HLA-B27: 80%.   The subgroup in which least 
data were available was the subgroup of ReA: radiographs: 38%; MRI: 13%; and HLA-B27: 71%. In 
the subgroup of patients with chronic back pain (past history or current), radiographs were required 
as complementary testing in the majority of these patients (85%) and less frequently MRI-SI (28%). 
Patients with back pain in which imaging was performed, sacroiliitis on radiographs was detected 
in 54%, and MRI-SI inflammation in 56%. HLA-B27 testing was performed in 80.1% of these patients, 
and 43.6% of them were positive.  
 
Performance of classification criteria 
In total, 538 of the 581 patients (93%) in the cohort met at least one criteria set: ASAS: 81% (43.4% 
had axSpA, and 37.2% had pSpA); ESSG: 74%; Amor: 53%; and 69% (n=399) of patients met two 
criteria sets. When MRI was used as a substitute for radiographic sacroiliitis, the classification rate 
slightly increased to 75% for ESSG and to 58% for Amor. The performance of each criteria set is 
summarized in table-2. All patients with a diagnosis of AS by the rheumatologist fulfilled at least 
one of these three criteria sets, and 56% of these patients fulfilled all three criteria sets. In 
particular, patients with a clinical diagnosis of ReA (40%) and uSpA (35%) often fulfilled all three 
criteria sets, which may reflect the degree of overlap in the criteria for those disease subtypes. 
Evaluating the ESSG and Amor-criteria, the addition of MRI instead of radiographs to the criteria set 
did not substantially modify the level of concordance with the ASAS-criteria, which increased from 
71.3% to 72.5% and from 57.1% to 60.9% respectively (table-3). 
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Table 2. Number and proportion of patients meeting the different 
criteria sets. The classification rate was defined as the proportion of 
patients fulfilling a particular classification criteria set. 
 
Criteria set N=581 (%) CI (95%) 
 
ASAS SpA criteria 
 
   468 
 
      80.6   
 
77.1 – 84.7 
     ASAS axial SpA 
          Imaging arm 






  9.3 
39.3 – 47.5 
     ASAS peripheral SpA 216 37.2 33.2 – 41.3 
ESSG criteria 431 74.1 70.4 - 77.7 
      ESSG with MRI pos included* 438 75.4 71.7 – 78.9 
Amor criteria 309 53.1 49.0 – 57.3 
      Amor with MRI pos included* 335 57.7 53.5 – 61.7 
    
*Inclusion of MRI as a surrogate for radiographic damage of sacroiliitis (active 
inflammatory changes) into the original criteria. ESSG, European Spondylarthropathy 
Study Group; ASAS, Assessment of Spondyloarthritis international Society; MRI, 
magnetic resonance imaging.  
 
 
Table 3. Concordance among the different classification criteria sets. 
 
Criteria ASAS SpA ESSG 
ESSG 
+MRI Amor 
ESSG 71.3 - - - 
ESSG + MRI* 72.5 98.5 - - 
Amor 57.1 70.4 69.2 - 
Amor + MRI* 60.9 72.2 72.6 95.5 
 
*Inclusion of MRI as a surrogate for radiographic damage of sacroiliitis (active inflammatory 
changes) into the original criteria. ESSG, European Spondylarthropathy Study Group; ASAS, 
Assessment of Spondyloarthritis international Society; MRI, magnetic resonance imaging. 
 
 
No single SpA feature explained differences in the fulfilment of classification criteria. Chronic back 
pain, IBP, enthesitis and alternating buttock pain were significantly more common in those patients 
meeting all three criteria sets compared with those who did not meet any of the criteria, 
nevertheless these features were frequently present in both groups (table-4).  Interestingly, in the 
group of patients who fulfilled ESSG or Amor but not the ASAS-criteria, HLA-B27 positivity was 
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remarkably lower (4.5%) than in those who did not fulfil ASAS and ESSG-criteria (46%) or ASAS and 
Amor-criteria (41%).  Additionally, CRP values were higher in the group of patients who did not fulfil 
any of the criteria compared with those who fulfilled all criteria.  
 
The overlap in criteria fulfillment (figure-1) was presented using a Venn-diagram representing the 
numbers of patients with any clinical diagnosis of SpA fulfilling each criteria set. A substantial 
percentage of patients (42%, n=244) met ASAS and ESSG as well Amor-criteria. In contrast, relevant 
numbers of patients with a clinical diagnosis of SpA fulfilled one classification criteria set exclusively: 
Only ASAS-axSpA: 49 patients; only ASAS-pSpA: 33 patients; only ESSG: 25 patients; and only Amor-

















  Table 4. Comparison of the characteristics of patients fulfilling (+) and not fulfilling (-) each criteria set. 
 
Characteristic 
ASAS SpA ESSG Amor 
(+) (-) p (+) (-) p (+) (-) p 
Male gender, N (%) 343 (73.3) 74 (65.5) 0.098 297 (68.9) 120 (80) <0.001 208 (67.3) 209 (76.8) 0.011 
Age, (years) 35.4±13.7 33.5±12.8 0.256 35.8±13.5 32.5±13.4 0.030 36.1±13.3 33.6±13.7 0.051 
Age at first symptom 
(years) 
28±10.9 27.9±9.2 0.887 28.3±10.7 26.9±10.4 0.220 28.8±11.1 26.8±9.8 0.051 
Symptom duration 
(years) 
7.6±9.9 6.0±8.9 0.188 7.6±9.8 6.4±9.3 0.319 7.5±9.3 7.1±10.4 0.653 
Chronic back 
pain, N (%) 
369 (78.9) 70 (62) <0.001 335 (77.7) 104 (69.3) 0.039 254 (82.2) 185 (68) <0.001 
IBP, N (%) 227 (48.5) 31 (27.4) <0.001 202 (46.9) 56 (37.3) 0.043 141 (45.6) 117 (43) 0.527 
Buttock pain, N (%) 146 (31.2) 26 (23) 0.087 144 (33.4) 28 (18.7) <0.001 112 (36.3) 60 (22.1) <0.001 
Asymmetric 
oligoarthritis, N (%) 
353 (75.2) 67 (59.3) <0.001 306 (71.0) 113 (75.3) 0.308 222 (71.8) 197 (72.4) 0.876 
Enthesitis, N (%) 287 (61.3) 45 (39.8) <0.001 266 (61.7) 66 (44) <0.001 211 (68.3) 121 (44.5) <0.001 
Dactylitis, N (%) 76 (16.2) 8 (7.1) 0.013 68 (15.8) 16 (10.7) 0.125 55 (17.8) 29 (10.7) 0.015 
Pos family history,  
N (%) 
28 (6) 3 (2.7) 0.158 27 (6.3) 4 (2.7) 0.091 20 (6.5) 11 (4) 0.194 
Preceding Infection,  
N (%) 
175 (37.4) 35 (31) 0.202 149 (34.6) 61 (40.7) 0.181 104 (33.7) 106 (39) 0.183 
Uveitis, N (%) 31 (6.6) 4 (3.5) 0.216 25 (5.8) 10 (6.7) 0.701 24 (7.8) 11 (4) 0.060 
Psoriasis, N (%) 9 (1.9) 18 (15.9) 0.281 16 (3.7) 11 (7.3) 0.07 13 (4.2) 14 (5.1) 0.591 
IBD, N (%) 3 (0.6) 2 (1.7) 0.451 5 (1.1) 0 (0) 0.185 4 (1.2) 1 (0.3) 0.227 
 
HLA-B27 positive,  
N (%) 
191 (51.3) 3 (4.5) <0.001 143 (43.3) 51 (46) 0.631 112 (46.3) 82 (41.2) 0.285 
CRP (mg/dl) 10.4±34.9 16.5±34.8 0.342 9.2±2.7 19.1±6.6 0.100 9.4±3.6 14.3±3.8 0.345 
ESR (mm/hr) 25.9±17.5 22.4±18.2 0.159 24.4±17.2 27±19 0.256 22.7±16 27.3±18.9 0.025 
Sacroiliitis X-ray,  
N (%) 
158 (53.7) 0 (0) - 121 (46) 37 (45.1) 0.888 97 (50) 61 (40.4) 0.076 
Sacroiliitis MRI,  
N (%) 
69 (58.5) 0 (0) - 54 (50) 15 (51.7) 0.869 37 (50.7) 32 (50) 0.936 
          
 
Continuous variables were compared by t-test and categorical variables were compared by Chi-square test Values are given as the    
means (SD) for the continuous variables as a percentages for the categorical variables, unless otherwise specified.  
AS, ankylosing spondylitis; uSpA, undifferentiated spondyloarthritis; ReA, reactive arthritis; PsA, psoriatic arthritis; IBD, SpA 
associated with inflammatory bowel disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MRI, magnetic 
resonance imaging; BASFI, Bath Ankylosing Spondylitis Functional Index; BASDAI, Bath Ankylosing Spondylitis Disease 






Figure 1. Number of patients meeting the original classification criteria for spondyloarthritis and 






















ESSG, European Spondylarthropathy Study Group; ASAS, Assessment of Spondyloarthritis international Society. 
 
 
Most important, however, is to investigate how ASAS-criteria fulfillment relates to clinical diagnosis. 
This analysis is visualized in the Venn-diagram in Figure-2: All patients with a clinical diagnosis of AS 
fulfilled the axSpA-criteria, and all patients with a clinical diagnosis of ReA fulfilled pSpA-criteria. 
The other subcategories of clinical diagnoses, however, were either captured by axSpA-criteria or 
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Not fulfilling any criteria set 


























Figure 2. Number of patients meeting the ASAS classification criteria according to clinical diagnosis 


























ASAS, Assessment of Spondyloarthritis international Society; AS, ankylosing spondylitis; uSpA, undifferentiated SpA; 




Figure-3 and Table-3 describe criteria overlap in two manners: Table-3 describes the concordance 
rates between ASAS, ESSG and Amor, as well as these rates with MRI-modified ESSG and Amor-
criteria. Concordance between ASAS and ESSG is approximately 70% and between ASAS and Amor 
approximately 60%. Of note, the concordance rates did not increase significantly by substituting 
the radiologic criterion by the MRI criterion. Figure-3 starts with a clinical diagnosis of SpA. The 
large majority of patients with a clinical diagnosis fulfill any of the existing criteria, but there is 
marked heterogeneity in doing so: all combinations of criteria can be found, and there is only a 
small fraction of patients that classifies consistently negative.  
AS 
n=169 
















































Figure 3. Cumulative effect of the classification rate according to the proportion of patients who 
fulfill (+) and those who did not fulfil (-) the original criteria in all patients with a clinical diagnosis 







This study has shown that the ASAS-criteria are most sensitive in classifying patients as having SpA, 
using the rheumatologist’s clinical diagnosis as an external standard. The ASAS-criteria were more 
sensitive than the ESSG and Amor, even if these latter were supplied with information about 
sacroiliitis on MRI as a SpA feature. The addition of MRI, however, did not substantially increase the 
classification rate of the ESSG and Amor and did not importantly influence the concordance rate 




































A moderately high degree of concordance (50-70%) was observed among the different criteria sets 
using the clinical diagnosis as the external reference, adding to the credibility of the concept that 
these criteria classify a considerable proportion of patients with similar and rather homogeneous 
characteristics. While none of the single SpA feature was particularly important in explaining 
differences in the fulfilment of several sets of classification criteria, chronic back pain, IBP, enthesitis 
and alternating buttock pain were the parameters that particularly differed between patients with 
a clinical diagnosis of SpA fulfilling and those not fulfilling the criteria. This means that Colombian 
physicians in this clinic tend to consider a diagnosis of SpA if patients present with these 
characteristics. These features were remarkably similar across all criteria, which suggests that they 
are among the core characteristics of SpA, which is entirely in line with the ‘Gestalt’ -the ‘picture’- 
of this disease. 
 
The results of this study allow interesting interpretations about how rheumatologists in this clinic 
in Colombia make a clinical diagnosis of SpA. The rate of HLA-B27 positivity in the group of patients 
with a clinical diagnosis of SpA who did not fulfill the ASAS-SpA criteria was low, and was lower than 
in those patients with a clinical diagnosis of SpA not fulfilling other criteria sets for SpA. This low 
rate of HLA-B27 in those patients contrasts with the prominent role of HLA-B27 as the entry 
criterion in the clinical arm of axSpA-criteria, and as a SpA feature in both axial and peripheral ASAS 
SpA-criteria. Apparently, rheumatologists did not pay too much attention to the presence or 
absence of HLA-B27 when considering a clinical diagnosis of SpA, which is in line with the widely 
disseminated message in the past that many healthy individuals may be HLA-B27 positive without 
having AS 17. Furthermore, patients who did not fulfil any of the criteria sets, had a higher CRP level 
than patients who fulfilled at least one the criteria sets. Apparently, the rheumatologist still 
diagnosed them as having SpA. It seems that a clinical diagnosis of SpA is more easily made when 
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signs of inflammation are present, even though characteristic features of SpA may be lacking or 
insufficiently present.  
 
AS as a clinical diagnosis implied the fulfillment of more criteria sets. Patients with AS had the 
highest availability of important tests (imaging and HLA-B27), as compared with other subtypes. 
Apparently, physicians who suspect a patient of having AS often test not only HLA-B27 but also ask 
for MRI, even though both a HLA-B27 and an MRI result are formally redundant. This finding 
regarding additional testing was similar when analyzing patients who had chronic back pain. 
Interestingly, these tests were far less frequently ordered if a patient had ReA or uSpA, while in the 
context of current thinking, they would have been most useful to corroborate a clinically made 
diagnosis. Explanations could be that in case of a patient with ‘clinical AS’ the physician wants to 
have supportive information, for example because the pelvic radiograph is often equivocal 18, which 
may lead to the fulfillment of more criteria sets. In case of ReA, on the other hand, the physician 
may not consider the disease as part of the (axial) SpA-spectrum and does not require supportive 
tests, which will lead to the fulfillment of less criteria sets. In support of this thesis, we could 
delineate a considerable number of patients with a clinical diagnosis of SpA who fulfilled only one 
set of classification criteria: these patients often had a diagnosis of uSpA or ReA.  
 
Our results are in concordance with other studies reporting on the validity of the ASAS-criteria in a 
clinical rheumatology setting using the clinical diagnosis as reference standard.  The DECLIC-study 
19 performed in patients with chronic back pain, the SPACE-cohort 20, which is a cohort of patients 
younger than 45 years with chronic back pain lasting between 3 months and 2 years, and the 
Spanish ESPERANZA-program 21, which includes patients referred to clinics for early SpA, all found 
that the ASAS-criteria had a higher sensitivity when tested against a clinical diagnosis of axSpA than 
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the ESSG or Amor-criteria. In contrast, in the DESIR22 cohort (patients with recent onset of 
inflammatory back pain) a higher sensitivity was found for the Amor and ESSG criteria (79 and 78%) 
as compared to ASAS criteria (70%).  
 
The results of this study are also in line with previous Latin-American studies reporting a higher 
presence of peripheral manifestations in SpA (Latin-America 23 and Colombia 24,25,26). The high 
frequency of arthritis (72%) and enthesitis (57%) in our study are also in concordance with findings 
in Mexican mestizo 27 patients (peripheral arthritis in 66% and enthesitis in 47%) that had 
predominant involvement of lower limbs. Brazilian SpA-patients reported entheseal involvement in 
54% 28. Similarly, in a study comparing the clinical expression of patients with AS between Latin-
America and Europe 29 a higher frequency of peripheral arthritis (57% vs 42%) and enthesitis (54% 
vs 38%) was found in Latin-America. The GESPIC-Cohort 30 only reported peripheral arthritis being 
present in 14% of the AS patients and in 18% of the in non-radiographic axSpA. Similar findings were 
reported for enthesitis.  
 
The frequency of HLA-B27 in our cohort was also rather low, not only in AS (63%) but also in SpA in 
general (44%), as compared to the frequency of HLA-B27 in AS patients in Europe and North 
America (80-90%) 31. This rather low frequency was similar to other studies in Latin America 32 and 
was similar to data recently reported in a Colombian study analyzing HLA-alleles33, finding a 
frequency of HLA-B27 of 40% in SpA patients. This may be explained by differences in the 
prevalence of HLA-B27 in the general population, which has a wide ethnic and geographic variation.  




There is an important problem regarding the interpretation of the performance of criteria in 
observational studies like ours. In some observational studies, such as SPACE and DESIR, MRI and 
HLA-B27 testing are performed in all patients ‘by protocol’, regardless of the likelihood of a 
diagnosis of SpA. In other observational SpA cohorts, including the Colombian cohort, many of these 
tests are performed on clinical indication only, namely in those patients with the highest probability 
of having SpA, or –alternatively- in those in whom the presence of other SpA-features does not 
convince the diagnosing physician. Here the danger of bias by indication arises, because the 
presence of a certain test result may reflect the perceived severity of the disease, and consequently 
information about these tests in patients with milder symptoms may be lacking. Additionally, the 
lack of information about HLA-B27 and MRI in a proportion of patients could have influenced the 
performance of the classification criteria, since these parameters (HLA-B27 and MRI) have a rather 
prominent place in the classification criteria (HLA-B27 in the Amor criteria and HLA-B27 and MRI in 
the ASAS classification criteria). It is unclear how this lack of data may have impacted the results.   
 
There are several limitations in this study, including the retrospective design and missing data, 
which reflects the daily clinical practice. First, there was not a fixed protocol requesting for 
additional clinical testing for the totality of patients; in contrast, these test were performed based 
on the opinion of the physician. Second, we selected the rheumatologist diagnosis of SpA as the 
external standard. A concern with our choice of external standard is that the rheumatologist´s 
diagnosis might be biased and influenced by current knowledge, by the experience and the existing 
criteria classification sets, by new diagnostics developments (MRI) or by discussion with experts. 
Third, data were only collected at the initial visit to the clinic (cross-sectional approach) and there 
was no information of follow-up visits available, not information about (response to) treatment.  
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The strength of this study is that the data were collected before the establishment of the ASAS-
criteria. The clinical diagnosis in many rheumatic conditions such as SpA is made based on a 
combination of suggestive symptoms, physical examination findings and complementary testing; 
therefore, it is guided largely by the “gestalt” rather than quantitative items. These factors could 
indeed influence the clinical diagnosis and therefore the request of additional testing. On the other 
hand, this is what is happening in clinical practice to define prognosis and start treatment. 
 
In conclusion, compared with the ESSG and Amor, the ASAS-criteria classify more patients as having 
axial or peripheral SpA when the rheumatologist’s diagnosis is used as an external standard. 
Although Colombian physicians in this clinic do not perform HLA-B27 testing or imaging in all 
patients suspected of having SpA, they do require these tests if the clinical symptoms fall short and 
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Objective To evaluate the patients’ characteristics associated with the clinical decision to request 
SI-MRI and/or HLA-B27 in patients with SpA in daily practice.  
Methods Patients referred to a rheumatology outpatient-clinic in a national referral-centre were 
selected. Patients with a clinical diagnosis of SpA according to the rheumatologist were included. 
SI-MRI and HLA-B27 was available for patients in whom the rheumatologists had ordered these 
tests. Characteristics associated with ordering SI-MRI or HLA-B27 were identified with univariable 
analyses. Variables with p-value <0.05 and > 80% completeness were selected for further analysis. 
A multivariable logistic regression analysis was used to evaluate the determinants related with the 
decision to perform SI-MRI and/or HLA-B27 and odds ratios with 95% confidence intervals were 
calculated. 
Results In total, 581 patients with SpA were included in the cohort, 72% were men, mean age 
34.6±12.1 and disease duration 7.3±9.7 years. Of these patients, 24% (n=137) had SI-MRI and 77% 
(n=441) had HLA-B27 tests ordered. Independently predictive factors for ordering a SI-MRI were 
the presence of IBP (OR=1.81), enthesitis (OR=1.57) and the number of initial-symptoms at 
presentation (OR=1.27 per additional symptom present). Independently predictive factors of HLA-
B27 testing were the number of initial-symptoms (OR=1.45 per symptom) and uveitis (OR=3.19). 
Conclusions. This study strongly suggests that rheumatologists use certain clinical clues to decide if 
they order expensive and scarce tests in the diagnostic work-up of SpA patients. These 
manifestations may increase the efficiency of these tests in clinical practice and suggest that clinical 







Spondyloarthritis (SpA) comprises a heterogeneous group of related diseases that are genetically 
linked and share characteristic clinical features associated with the inflammation of sacroiliac joints 
and the presence of HLA-B27 1.  Clinically, SpA patients may present with axial and peripheral joint 
manifestations, entheseal involvement, and extra-articular features, such as uveitis and psoriasis 2. 
In addition to clinical findings, imaging [radiography and sacroiliac joint magnetic resonance 
imaging (SI-MRI)] 3 and laboratory data [HLA-B27 and C-reactive protein (CRP)] 4 are important 
diagnostic tools in clinical practice. 
 
In the last two decades, MRI has been increasingly used to assess patients with clinically suspected 
SpA 5. Currently, MRI has become an important tool in SpA and its introduction as a diagnostic test 
for SpA has been a major advance 6, mainly because active inflammatory lesions are visible on MRI 
long before definite lesions on conventional radiographs are detectable 7. It makes MRI the most 
sensitive imaging modality available for the detection of sacroiliitis.  
 
Since the role of HLA-B27 as a marker of AS has first been reported in 1973, its potential role in the 
diagnosis, prognosis and management of SpA has been extensively investigated. HLA-B27 is known 
to be associated with earlier age at disease onset in ankylosing spondylitis (AS) 8, increased severity 
and persistence of SI-MRI- inflammation in patients with inflammatory back pain (IBP) 9 and with a 
higher likelihood of a positive SI-MRI in patients with early IBP 4. Additionally, HLA-B27 has been 
associated with anterior uveitis in SpA patients 10. 
 
The relevance of MRI and HLA-B27 as central parameters in defining the spectrum of SpA is obvious 
for many reasons: First, these parameters have been included in the classification criteria: HLA-B27 
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in Amor criteria 11 and both (SI-MRI/ HLA-B27) in the ASAS classification criteria. In the ASAS axial-
SpA criteria 12, two “anchor criteria” were defined in combination with SpA features: the “imaging 
arm” requires the evidence of sacroiliitis by imaging and the “clinical arm” requires the presence of 
the HLA-B27 antigen. In peripheral-SpA 13, sacroiliitis on MRI and HLA-B27 were included as 
additional SpA features.  Second, sacroiliitis by MRI and HLA-B27 positivity have been selected as 
feasible screening methods for axial-SpA 14, and have been included in the decision tree of the 
original and modified Berlin diagnostic algorithm advised to be used by rheumatologists in daily 
practice 15. Recently, these two tests were included in the list of parameters of the ASAS-endorsed 
recommendation for early referral of patients suspected of having axial-SpA by primary care 
physicians or non-rheumatologists 16. Moreover, in an international survey about referral, diagnosis 
and management in axial-SpA 17, rheumatologists reported that they belief strongly in imaging 
(MRI) and systematically request HLA-B27-typing when evaluating a patient in their daily practice. 
However, these tests are rather costly, and waiting time for MRI is long in many countries. 
Therefore, many recommend to pre-select patients for HLA-B27 testing and SI-MRI in order to 
increase diagnostic yield. 
 
Knowledge about criteria to order MRI and/or HLA-B27 in patients suspected of SpA, is rather 
limited. Since imaging MRI and HLA-B27 are a fundamental part of the ASAS classification criteria, 
and are considered important elements in the early referral and diagnosis of patients, it is expected 
that the decision about whether or not to order one or both of these tests will become increasingly 
important. Therefore, the aim of the present study was to identify and evaluate the patient´s 
characteristics associated with the clinical decision to ask SI-MRI and/or HLA-B27 in the diagnostic 





Study design and data collection 
A cohort of consecutive patients referred to a single-center rheumatology outpatient clinic in 
Colombia were included at the first visit to the clinic between January-2002 and June-2010. Detailed 
information of the cohort has been published previously 18. Patients with a clinical diagnosis of SpA 
by one of two rheumatologists considered experts in the field (RV, JL) were selected and included. 
Patient information was collected based on data from the clinical record. The institutional ethics 
committee approved this study, conducted under the principles of the Helsinki declaration. Patients 
signed informed consent to collect, file and use the data. 
 
We collected data related to demographic and clinical parameters such as gender, age at 
assessment, age at symptoms onset, symptoms at presentation, disease duration and preceding 
infection. Furthermore, data on past (history) and present (current)  SpA features were collected: 
chronic back pain, IBP, alternating buttock pain, asymmetric oligo-arthritis (predominantly in lower 
limbs), enthesitis (heel pain), dactylitis (sausage digit), uveitis (confirmed by an ophthalmologist), 
psoriasis and inflammatory bowel disease (IBD). The rheumatologists assessed the patients and 
provided the clinical diagnosis categorized by subtypes (AS, undifferentiated SpA, reactive arthritis, 
psoriatic arthritis and SpA associated to IBD). The number of classification criteria met, which was 
retrospectively assessed per patient (ESSG, Amor, and ASAS) and the number of SpA features, were 
included as explanatory variables. The patients’ disease characteristics, including the Bath 
Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index 
(BASFI), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were assessed. The 




Outcome measurement  
The outcome of interest in the current analyses was the request of SI-MRI or HLA-B27 by the 
rheumatologists. Information of this outcome was retrieved from the clinical file with a description 
of the test result as recorded in the medical chart. If information about SI-MRI or HLA-B27 was 
found, it was considered that this specific test had been requested by the rheumatologist (who 
decided to ask these test). Sacroiliitis on MRI was defined according to the local experienced 
musculoskeletal radiologist’s interpretation of the presence of active inflammatory changes in the 
SI-joint 20. According to usual clinical practice, no central reading was done. The HLA-B27 test was 
performed locally in the laboratory of immunology. 
 
Statistical analysis 
Descriptive statistics were used to calculate mean (± SD) for continuous data and percentages for 
categorical data. Explanatory variables were “SI-MRI-ordered” (yes vs no) and “HLA-B27-ordered” 
(yes vs no).  
Age at symptom onset, age at assessment, symptoms at presentation and disease duration had less 
than 20% of missing data. BASFI, BASDAI, ASDAS-CRP, ASDAS-ESR, CRP and ESR had more than 20% 
of missing data. All other explanatory variables had complete data. In case of missing data, 
imputation was performed by using the median or mode from the variable’s distribution as 
appropriate, but only variables with complete data in at least 80% of the cohort were included in 
the multivariable analysis (see below).  
Patient´s characteristics were examined per subgroups of SI-MRI ordered (yes vs no) or HLA-B27 
ordered (yes vs no) and analysed by univariable analysis (either by chi-square or by t-test if 
appropriate) followed by logistic regression analysis. Variables with a p-value <0.05 in univariable 
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analysis were entered in a (backward selection) multivariable analysis if data availability was at least 
80%, with SI-MRI ordered or HLA-B27-ordered as dependent variables.  
Based on the hypothesis that IBP will primarily lead to ordering SI-MRI in male patients and in those 
that have short disease duration, interactions of characteristics with gender (male/female) and with 
disease duration (short/long) respectively were tested. Potentially relevant interactions (p≤0.1) 
were found with age of symptoms onset and age of assessment. These interactions were weak, not 
considered clinically relevant and not reported. 
In the logistic regression analysis, the following variables were excluded because of too much 
missing information (≥20% of the cohort): BASFI, BASDAI, CRP, ESR, ASDAS-CRP and ASDAS-ESR.  In 
addition, IBD and age of symptom onset were excluded because of collinearity. Statistical analyses 




In total 581 patients with a clinical diagnosis of SpA were analysed. Most of them (72%) were males 
with a mean (SD) age of 34.6 (12.1) years, age at symptom onset of 28 (10.3) years and disease 
duration of 7.3 (9.7) years. Sixty percent of the cohort had less than 5 years of disease duration. 
Disease activity was rather high in the patients with axial SpA: BASDAI 5.4 (2.4), ASDAS-ESR 3.0 (0.9), 
and ASDAS-CRP 2.6 (0.8), and also in patients with peripheral SpA as assessed by the ASDAS-CRP 
(2.3 (0.9)).  Information on SI-MRI and HLA-B27 was available in a varying proportions of the 
patients, ordered at the instigation of the rheumatologist: of all patients, 137 patients (24%) had 




Demographic and disease characteristics of patients in whom an SI-MRI was ordered 
In univariable analysis, male gender, the number of symptoms at presentation, short disease 
duration, chronic back pain, IBP, enthesitis, no history of arthritis, no history of psoriasis, lower CRP, 
ESR and ASDAS-CRP were associated with a request for SI-MRI. 
 
In multivariable analysis, factors remaining independently associated with ordering SI-MRI were IBP 
(OR = 1.81, CI 95% [1.13–2.90], p = 0.01), enthesitis (OR = 1.57, CI 95% [1.00–2.49], p = 0.04) and 
the number of symptoms at presentation (OR = 1.27 per additional symptom, CI 95% [1.10–1.47], 


















Table 1.  Comparison of demographic and SpA disease characteristics according to SI-MRI-ordered 
status (n=581) 
Explanatory variables 
SI-MRI ordered Yes 
n=137 
SI-MRI ordered No 
n=444 p-value 
 
Male gender, (%) 
87 (63.5) 330 (74.3) 0.01 
Age at assessment, (years)* 33.5 ± 11.8 34.9 ± 12.2 0.46 
 (n=136) (n=329)  
Age symptom onset (≤35 yrs) (%)* 115 (83.9) 365 (82.2) 0.64 
 (n=133) (n=329)  
Symptoms at presentation (%)*    
          Arthritis 32 (23.4) 173 (38.9) ≤0.001 
          Enthesitis 8 (5.8) 24 (5.4)  
          Back pain 43 (31.4) 180 (40.5)  
          Butock pain 4 (2.9) 5 (1.1)  
          Several symptoms 48 (35) 58 (13.1)  
 (n=136) (n=335)  
Disease duration (≤5 years) (%) 52 (37.9) 123 (27.7) 0.02 
 (n=131) (n=332)  
Chronic back pain, (%) 123 (89.8) 316 (71.1) ≤0.001 
IBP, (%) 88 (64.2) 170 (38.2) ≤0.001 
Buttock pain, (%) 48 (35) 124 (27.9) 0.11 
Arthritis, (%)           88 (64.2) 331 (74.5) 0.01 
Enthesitis, (%) 97 (70.8) 235 (52.9) ≤0.001 
Dactyilitis, (%) 21 (15.3) 63 (14.1) 0.74 
Uveitis, (%) 10 (7.3) 25 (5.6) 0.47 
Psoriasis, (%) 2 (1.5) 25 (5.6) 0.04 
Infection history, (%) 36 (26.3) 174 (39.2) 0.006 
BASFI (≥4) (%)* 103 (75.2) 369 (83.1) 0.03 
 (n=127) (n=239)  
BASDAI (≥4) (%)* 113 (82.4) 370 (83.3) 0.81 
 (n=127) (n=239)  
ASDAS CRP high (≥2.1) (%)* 111 (81) 434 (97.7) ≤0.001 
 (n=80) (n=59)  
ASDAS ESR high (≥2.1) (%)* 125 (91.2) 412 (92.8) 0.47 
 (n=84) (n=162)  
CRP (≥5mg/dl) (%)* 12 (8.8) 143 (32.2) ≤0.001 
 (n=81) (n=97)  
ESR (≥20 mm/hr) (%)* 86 (62.8) 364 (81.9) ≤0.001 
 (n=84) (n=218)  
Diagnostic subtype (%)    
          Ankylosing spondylitis 44 (32.1) 125 (28.1) 0.001 
          Undifferentiated SpA 70 (51.1) 160 (36)  
          Reactive arthritis 20 (14.6) 136 (30.6)  
          Psoriatic arthritis 2 (1.5) 19 (4.3)  
          IBD 1 (0.7) 4 (0.9)  
Number of SpA features  2.2 ± 1.1 1.9 ± 1.1 0.18 
Number of criteria met 2.18 ± 0.8 2.05 ± 0.9 0.64 
Values are mean ± SD for continuous variables or percentages for categorical variables, unless otherwise specified. p-
values were calculated using t-test adjusted for unequal variances for comparison of continuous variables and Chi 
square test for categorical variables.  
IBP, inflammatory back pain, CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IBD, SpA associated to 
Inflammatory Bowel Disease; SI-MRI, sacroiliac joints magnetic resonance imaging; BASFI, Bath Ankylosing Spondylitis 
Functional Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Ankylosing Spondylitis Disease 
Activity Score.  
* Variables with missing data, n means the number of patients in which these variables are based.  
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Table 2. Association of demographic and SpA disease characteristics 
that independently prompt to ordering SI-MRI.  Results from a 
multivariable logistic regression model 
 
Explanatory variables 
SI-MRI ordered  
OR (95% CI) p Value 
Male gender (male vs female) 0.79 (0.50-1.22) 0.28 
Number of symptoms at presentation                             
(per additional symptom) 
1.27 (1.10-1.47) ≤0.001 
Disease duration (per year) 0.90 (0.57-1.41) 0.66 
Chronic back pain (yes vs. no) 1.57 (0.72-3.23) 0.26 
Inflammatory back pain (yes vs. no) 1.81 (1.13-2.90) 0.01 
Arthritis (yes vs. no) 0.85 (0.54-1.33) 0.48 
Enthesitis (yes vs. no) 1.57 (1.00-2.49) 0.04 
Uveitis (yes vs. no) 1.08 (0.48-2.41) 0.85 
Psoriasis (yes vs. no) 0.25 (0.53-1.20) 0.08 
Infection history (yes vs. no) 0.82 (0.49-1.37) 0.46 
Diagnostic subtype 1.06 (0.78-1.43) 0.68 
                  SI-MRI, sacroiliac joints magnetic resonance imaging 
 
Demographic and disease characteristics of patients in whom HLA-B27 was ordered 
In univariate analysis, the number of symptoms at presentation, the presence of IBP, uveitis, lower 
CRP, ESR and ASDAS-CRP were associated with a request for HLA-B27 testing. 
In multivariable analysis, the single factor remaining independently associated with ordering HLA-
B27 was the number of symptoms at presentation (OR = 1.45 per additional symptom, CI 95% [1.24–
1.71], p < 0.001). Although uveitis was associated in the univariable analysis with a request for HLA-
B27, it just missed statistical significance in multivariable analysis (OR = 3.19, CI 95% [0.94–10.87], 











Table 3. Comparison of demographic and SpA disease characteristics according to HLA-B27-
ordered status (n=581) 
Explanatory variables 
HLA-B27 ordered  
Yes (n=441) 
HLA-B27 ordered   
No (n=140) p-value 
 
Male gender, (%) 
311 (70.5) 106 (75.7) 0.23 
Age at assessment, (years)* 34.4 ± 12 35 ± 12.3 0.70 
 (n=367) (n=98)  
Age symptom onset (≤35 years) (%)* 361 (81.9) 119 (85) 0.39 
 (n=364) (n=98)  
Symptoms at presentation (%)*    
          Arthritis 124 (28.1) 81 (57.9) ≤0.001 
          Enthesitis 25 (5.7) 7 (5)  
          Back pain 191 (43.3) 32 (22.9)  
          Buttock pain 8 (1.8) 1 (0.7)  
          Several symptoms 87 (19.7) 19 (13.5)  
 (n=373) (n=98)  
Disease duration (≤5 years) (%)* 132 (29.9) 43 (30.7) 0.86 
 (n=344) (n=89)  
Chronic back pain, (%) 341 (77.3) 98 (70) 0.07 
IBP, (%) 207 (46.9) 51 (36.4) 0.02 
Buttock pain, (%) 136 (30.8) 36 (25.7) 0.24 
Arthritis, (%)           313 (70.9) 106 (75.7) 0.27 
Enthesitis, (%) 255 (57.8) 77 (55) 0.55 
Dactyilitis,  (%) 61 (13.8) 23 (16.4) 0.44 
Uveitis,  (%) 32 (7.3) 3 (2.1) 0.02 
Psoriasis,  (%) 17 (3.9) 10 (7.1) 0.10 
Infection history, (%) 153 (34.7) 57 (40.7) 0.19 
BASFI (≥4) (%)* 353 (80) 119 (85) 0.19 
 (n=291) (n=75)  
BASDAI (≥4) (%)* 366 (82.9) 117 (83.6) 0.87 
 (n=291) (n=75)  
ASDAS CRP (high)  (%)* 407 (92.3) 138 (98.6) 0.02 
 (n=116) (n=23)  
ASDAS ESR (high) (%)* 403 (91.4) 134 (95.7) 0.15 
 (n=222) (n=36)  
CRP (≥5 mg/dl) (%)* 43 (9.8) 112 (80) ≤0.001 
 (n=142) (n=36)  
ESR (≥20 mm/hr) (%)* 333 (75.5) 117 (83.6) 0.04 
 (n=239) (n=63)  
Diagnostic subtype (%)    
          Ankylosing spondyltis 134 (30.4) 35 (25) 0.13 
          Undifferentiated SpA 179 (40.6) 51 (36.4)  
          Reactive arthritis 108 (24.4) 44 (31.4)  
          Psoriatic arthritis  12 (2.7) 9 (6.4)  
          IBD 3 (0.7) 1 (0.7)  
Number of SpA features 2.1 ± 1.1 1.8 ± 1.1 0.36 
Number of criteria met 2.1 ± 0.9 1.8 ± 1 0.23 
Values are mean ± SD for continuous variables or percentages for categorical variables, unless otherwise 
specified. p-values were calculated using t-test adjusted for unequal variances for comparison of continuous 
variables and Chi square test for categorical variables.  
IBP, inflammatory back pain, CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IBD, SpA associated 
to Inflammatory Bowel Disease; MRI, magnetic resonance imaging; BASFI, Bath Ankylosing Spondylitis 
Functional Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Ankylosing Spondylitis 
Disease Activity Score.  
* Variables with missing data, n means the number of patients in which these variables are based 
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Table 4. Association of demographic and SpA disease characteristics 
that independently prompt to ordering HLA-B27.  Results from a 
multivariable logistic regression model. 
 
Explanatory variables 
HLA-B27 ordered  
OR (95% CI) p Value 
Male gender (male vs female) 0.85 (0.53-1.36) 0.50 
Number of symptoms at presentation (per 
additional symptom) 
1.45 (1.24-1.71) ≤0.001 
Disease duration (per year) 1.26 (0.77-2.04) 0.34 
Chronic back pain (yes vs. no) 0.96 (0.53-1.73) 0.90 
Inflammatory back pain (yes vs. no) 1.14 (0.70-1.85) 0.58 
Arthritis (yes vs. no) 1.15 (0.70-1.89) 0.55 
Enthesitis (yes vs. no) 0.89 (0.58-1.38) 0.62 
Uveitis (yes vs. no) 3.19 (0.94-10.87) 0.06 
Psoriasis (yes vs. no) 0.71 (0.27-1.83) 0.48 
Infection history (yes vs. no) 11.01 (0.61-1.64) 0.96 
Diagnostic subtype 0.85 (0.63-1.15) 0.30 
 
DISCUSSION 
The result of this study confirm that rheumatologists working in clinical practice order additional 
tests such as SI-MRI and HLA-B27 cautiously (not in all patients), and base their diagnostic behaviour 
on clinical clues.  Characteristics associated with the decision to order SI-MRI and/or HLA-B27 in 
clinical practice, were the presence of IBP, enthesitis, the number of symptoms at presentation and 
uveitis. Of note, gender, disease duration, the presence of peripheral arthritis and/or psoriasis did 
not independently determine the behaviour of rheumatologists to request SI-MRI and/or HLA-B27 
testing. 
 
Apparently certain clinical manifestations are important. ‘Clinical clues’ make intuitive sense since 
they may convey the highest probability on a positive test result (either sacroiliitis on MRI or HLA-
B27 positivity) and therefore increase efficiency, optimize usage and save costs. This is true 
especially for AS 21, a disease that has a reportedly strong association with HLA-B27 and is related 
to the presence of axial manifestations. In contrast, clinicians apparently know that patients 
presenting with non-inflammatory mechanical back pain, peripheral arthritis or psoriasis for 
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example, may benefit more from other tests. Physicians do not ask for HLA-B27 (77%) or SI-MRI 
(only 24%) in all patients but when clinical symptoms are indicative but not confirmatory.  
 
It is also interesting to look at which factors did not contribute. Apparently, clinicians do not base 
their behaviour (of asking SI-MRI or HLA-B27) on the conventional appreciation that AS is a disease 
of males. Gender was not a factor that determined a SI-MRI or HLA-B27 request. That is a promising 
finding in light of the fact that many still consider females with SpA underdiagnosed in spite of 
findings suggesting that as many females as males may suffer from axial SpA 22. 
 
It is important to mention that this study has only addressed the performance of a test, and not the 
result of that test.  A recent study from the ESPeranza Cohort 23 has assessed the utility of SpA 
features to anticipate the presence (not the request) of sacroiliitis on MRI or a positive result of a 
HLA-B27 test in patients with suspected axSpA. They found that IBP according to the ASAS definition 
plus alternating buttock pain or IBP according to Calin criteria plus awakening in the second half of 
the night predicted the presence of sacroiliitis on MRI. Our study assigned IBP as a determinant for 
ordering SI-MRI. Together, these studies confirm that the presence of IBP according to certain 
expert-criteria not only evokes an SI-MRI-request, but also that this behaviour is rational in that the 
likelihood of a positive result increases. In analogy, we have found uveitis being predictive of 
ordering HLA-B27, while in the ESPeranza Cohort uveitis appeared to be the factor related to a 
positive HLA-B27 (LR+ of 2.6). This finding is also in line with previous studies reporting that a 
positive HLA-B27 test in a patient presenting with uveitis plus SpA features may increase the 




Clinical clues that guide the request of a SI-MRI or HLA-B27 can be useful in clinical practice, because 
of costs and waiting time for SI-MRI. A practice based on inexpensive and widely available clues 
may be cost-and time-efficient, and their importance may increase over time.   
 
This study has limitations.  First, the design was retrospective. Other factors than those that have 
been measured could have influenced the likelihood to request a SI-MRI or a HLA-B27-test.  Second 
the study may have suffered from missing data and from the necessary exclusion of variables with 
too many missing data. There was, for instance, an indication that SI-MRI and/or HLA-B27 has been 
preferentially requested in patients with increased acute-phase reactants (CRP and/or ESR). A 
univariate comparison was highly statistically significant, but the variables were missing in too many 
patients and were excluded from multivariable analysis. The high level of missingness for CRP and 
ESR suggests anyway that decisions of requesting additional tests are certainly not only based on 
CRP/ESR.  Third, the study only addresses one side of the entire spectrum: patients with a diagnosis 
of SpA. Patients in whom a diagnosis of SpA was not established, with or without a SI-MRI or a HLA-
B27 test, were not taken into consideration. This study can therefore never be interpreted as a 
diagnostic experiment that tests the value of SI-MRI and HLA-B27. This study only gives insight into 
the circumstances in which SI-MRI or HLA-B27 are requested. It is very reasonable to assume that 
expensive and scarce diagnostics such as SI-MRI and HLA-B27 tests are only considered if they may 
help the clinician to increase the likelihood of a suspected clinical diagnosis, but not if the clinician 
considers the likelihood of SpA as sufficiently high. In that situation, he may rather refrain from 
asking expensive and time-consuming tests. These Bayesian principles form the basis of proper 
clinical reasoning.  Finally, all patients of this study came from the same country and even the same 
centre, which importantly limits the external validity and the extrapolation of the findings to other 
countries and clinics. The results of this study should be interpreted in this context.  
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In conclusion, rheumatologists use certain clinical clues to decide if they order expensive and scarce 
tests in the diagnostic work-up of patients with SpA. These manifestations may increase the 
efficiency of these tests in clinical practice and suggest that clinical reasoning follows principles of 
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Objectives Increased risk of comorbidities has been reported in spondyloarthritis (SpA). The 
objective of this study was to determine the prevalence and risk of developing comorbidities in SpA-
patients in three Latin America (LA) countries, and to compare that prevalence with the general-
population. 
Methods Data from 390 SpA-patients enrolled in the ASAS-COMOSPA study from Argentina, 
Colombia and Mexico were analyzed. Age and gender standardized-prevalence (95%CI) was 
estimated for arterial-hypertension (AHT), tuberculosis (TB), and malignancies. Age-and gender-
specific data from general-population were obtained from CARMELA-study for AHT, Global TB-
report and GLOBOCAN-project for malignancies. Data analyzed for AHT was confined to Colombia 
and Mexico. The prevalence in SpA-patients was compared with the prevalence in general-
population per age- and gender-specific stratum resulting in standardized risk ratios (SRR). 
Results In total, 64% of the SpA patients were male with a mean age of 45(SD 14.7) years. The most 
common comorbidities in the three LA-countries were, AHT (25.3%, 95%CI 21.2-30.0), 
hypercholesterolemia (21.5%, 95%CI 17.6-26.0) and osteoporosis (9.4%, 95%CI 6.8-12.9). AHT-
prevalence in Colombia and Mexico was 21.4% (95%CI 15.4-28.9) and was increased compared to 
general-population (12.5%, 95%CI 11.4-13.7) resulting in an SRR of 1.5. TB-prevalence in the three 
LA-countries was 3.3% (95%CI 1.8-5.7), which was importantly higher than expected from general-
population (0.32%), leading to an SRR of 10.3. The prevalence of malignancies was not increased.  
Conclusions Patients with SpA in Latin-America are at increased risk of AHT and TB in comparison 







Comorbidities are frequently associated with inflammatory rheumatic diseases such as ankylosing 
spondylitis (AS), psoriatic arthritis (PsA) and rheumatoid arthritis (RA). In addition to the 
musculoskeletal manifestations for SpA and SpA-related extra-articular features (psoriasis, uveitis, 
inflammatory bowel disease (IBD)), patients may also have an increased risk of cardiovascular (CV) 
events, metabolic syndrome, malignancies and infections1, 2, 3. These comorbidities may result in 
premature-death4. 
 
The risk of developing comorbid conditions seems to be higher in patients with SpA than in the 
general population5, and these co-morbidities may manifest already shortly after the onset of initial 
symptoms6. CV events occur more frequently in AS patients, likely due to an increased prevalence 
of traditional risk factors (e.g. metabolic syndrome, arterial hypertension (AHT))7 ,8 ,9 and to the 
medications used for the treatment of SpA (e.g. non-steroidal anti-inflammatory drugs (NSAIDS). 
The increased risk of tuberculosis (TB) may be due to immune disturbances by the disease itself and 
by pharmacological immunosuppression10. Additionally, the risk of developing malignancies may be 
related to chronic inflammation and autoimmunity, although epidemiological evidence that AS is 
associated with the development of malignancy is lacking 11.        
 
The Assessment of SpondyloArthritis international Society of COMOrbidities in SpA (ASAS-
COMOSPA) study 12 is a cross-sectional observational study to assess comorbidities and their risk 
factors in SpA. This initiative included three Latin American (LA) countries, and provides an 
opportunity to explore the association of these comorbidities with SpA. While there are data in the 





The objective of this study was (1) to determine the prevalence of -and the risks to present -
comorbidities as assessed in the ASAS-COMOSPA-study –used as a reference group- in patients with 
SpA in three LA countries; and (2) to compare the prevalence of these with the information in the 




Study design and patient recruitment 
This was a cross-sectional study that used data from the worldwide ASAS-COMOSPA-study 12. Briefly, 
the ASAS-COMOSPA-study was an observational, multicenter and international study (22 countries 
from four continents) that included consecutive adult patients who fulfilled the ASAS SpA-criteria 
(axial or peripheral). The patients in the ASAS-COMOSPA-study enrolled from Argentina, Colombia 
and Mexico (one academic center in each country) were selected and analyzed for the present study. 
Additionally, 47 Colombian patients with data that made them eligible to ASAS-COMPOSPA but that 
were offered after the electronic database for the international study had been locked, were also 
included in this analysis. The results in which the Global ASAS-COMOSPA study data are reported in 
this study include the data from the LA countries. The study was approved by the Ethics and 
Research Committee of the Hospital Militar (No.C-2014-027) and was conducted according to the 
guidelines for good clinical-practice. All patients sign the informed-consent. 
 
Data collection 
Details of the data collection methods have been published previously 12. A case report form was 
used in the study to collect the data including patient’s demographics, SpA disease characteristics 





medications (NSAIDs, corticosteroids, conventional-synthetic and biologic-DMARDs) were also 
collected.  
 
The following comorbidities and risk factors for comorbidities were collected. AHT was defined as a 
history of AHT or use of anti-hypertensive therapy or a blood pressure at the study visit >140/90. 
TB was defined as a history or current active TB. Cancer was defined as a history of neoplasia in the 
colon, skin (melanoma and basocellular-carcinoma), lymphoma (Hodgkin’s and Non-Hodgkin’s 
disease), breast and cervix (for women) and prostate (for men). All data were collected by a study 
investigator by interview and were completed by reviewing medical records. The information was 
collected and registered in a centralized electronic-case report form.  
 
Data from the general population 
Total and gender- and age-group specific prevalence data for AHT of general population were ob-
tained from the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA-study). 
This is a population-based observational study (n=11,550) 13, 14 assessing the prevalence of cardio-
vascular risk-factors in seven Latin American cities including Buenos Aires, Bogotá and México City. 
The analyses of data of the general population for AHT was confined to Colombia and Mexico. We 
found a huge inter-country variability with regard to the AHT prevalence in the region, especially 
the data reported in Argentina. Whereas the AHT prevalence in the general-population in Colombia 
and Mexico was comparable (13 and 11% respectively), in Argentina the reported prevalence was 
29%. Because of this discrepancy, which can be explained by genetic, ethnic and demographic dif-
ferences between the countries in the region, the analyses for AHT was limited only to these two 






Prevalence data obtained from the general population of Argentina, Colombia and México were 
standardized for TB and malignancies. Specific prevalence data for TB stratified for gender and age 
categories have been obtained for the three countries using the 2015 Global Tuberculosis-report 15. 
This report is an initiative of the World Health Organization that provides comprehensive infor-
mation on the status of the disease at global and country levels. Regarding malignancies, gender- 
and age-group specific prevalence data have been obtained for the three countries using the 2012 
GLOBOCAN-project 16, 17. This initiative provides prevalence estimates for the major types of cancer 
worldwide.    
 
Statistical analyses 
Descriptive statistics were used for the demographic data, disease characteristics, disease activity, 
risk factors and the comorbidities of the patients included in the analyses. Data are presented as 
numbers (%) for qualitative variables and as the mean (SD) for continuous variables. The data were 
stratified for age categories and for males and females separately by comparing expected (general-
population) versus observed (Latin America) frequencies. Data from the Global ASAS-COMOSPA-
study was included for comparison with LA countries. In addition 95%CIs were estimated using the 
method described by Wilson 18, which is considered an accurate and precise method for calculating 
Cis 19 . Standardised risk-ratios (SRR) were determined to compare event rates (in this study, 
comorbidities and risk factors) in SpA patients vs. the general-population. SPSS Statistics 22 was 









In total, all 390 patients from the three countries Argentina (n=236), Colombia (n=85) and México 
(n=69) participating in the ASAS-COMOSPA-study were included in the analysis. Patient 
characteristics including demographic and disease characteristics by country, for the LA countries 
combined and the global study population -which includes information for the LA countries- are 
presented in table-1. In the LA countries, sixty-four percent were male, with a mean age of 45 (15) 
years and a mean disease duration since symptom onset of 7.0 (8.1) years. The proportion of 
patients with arthritis, enthesitis and dactylitis was higher in the three LA countries (74%, 62% and 
24%, respectively) as compared with all patients (n=3,984) in the ASAS-COMOSPA-study (56%, 38% 
and 16%, respectively). The usage of NSAIDS and DMARDS (particularly methotrexate) was higher 
in LA countries than in the entire ASAS-COMOSPA-study (72% and 48% respectively for NSAIDS, and 
68% and 33% respectively for DMARDS), whereas biological therapy was less frequently used (34% 
vs 44% respectively). The most common comorbidities and risk factors in all three LA countries were:  
AHT (25.3%)(95%CI 21.2 to 30.0), hypercholesterolemia (21.5%)(95%CI 17.6 to 26.0), osteoporosis 















Table 1. Demographic, disease characteristics and comorbidities of the Latin America countries and the global ASAS-
COMOSPA study 
All values are N (%) or mean (SD) for categorical and continuous variables, respectively  
IBD, inflammatory bowel disease  
 
Prevalence of comorbidities and risk factors 
The prevalence of AHT limited to SpA patients in Colombia and Mexico was higher (21.4%, 95%CI 
15.4 to 28.9) as compared to the general-population (12.5%, 95%CI 11.4 to 13.7) in these two 
countries. The prevalence of AHT was higher in men than in women, especially in the stratum of 55-
64 years (57% vs 11%, respectively) and also in patients ≥65 years (70% vs 25%, respectively), in 
whom cardiovascular risk is expected to be more similar in both genders. Additionally, in young 
patients (25-44 years) the prevalence of AHT was consistently increased in both genders compared 
to the general-population. All of these findings were consistent with the prevalence data of the 
global ASAS-COMOSPA-study. The total AHT risk of patients with SpA in Colombia and Mexico 






Argentina  Colombia México 
Number of patients 3984 390 236 85 69 
Male gender 65.0 63.8 61.9 60.0 75.4 
Age (years) 44 (14) 44.6 (14.7) 45.4 (14.5) 44.1 (13.9) 42.6 (16.3) 
Education level (university) 42.4 42.6 34.7 50.6 59.4 
Smoking status (current) 23.0 16.7 22.0 10.6 5.8 
Disease duration (years) 8.2 (9.4) 7.0 (8.1) 6.7 (8.3) 5.2 (5.6) 9.3 (8.7) 
Disease symptoms      
➢ Axial involvement 88.7 84.2 78.3 92.9 94.0 
➢ Arthritis 56.4 73.9 77.0 70.6 67.2 
➢ Enthesitis 38.0 62.5 57.9 77.6 59.7 
➢ Dactylitis 15.6 23.8 25.5 24.7 16.4 
➢ Uveitis 20.3 15.8 14.9 11.8 23.9 
➢ Psoriasis 22.5 23.0 33.2 4.7 10.4 
➢ IBD 5.2 3.3 3.4 3.5 3.0 
ASDAS-CRP 2.0 (1.1) 1.9 (1.1) 1.8 (1.1) 2.0 (1.0) 1.8 (1.4) 
BASFI 3.0 (2.7) 3.4 (2.8) 3.1 (2.8) 4.3 (2.2) 3.7 (3.0) 
NSAIDS use (last 3 months) 67.8 71.8 71.9 68.2 76.1 
Methotrexate (ever) 32.7 47.6 48.7 42.3 50.7 
Sulfasalazine (ever) 43.9 43.5 25.4 70.2 87 





was increased in women and in men (1.5 and 1.4 respectively) and consistent across different age 
groups, except in the stratum of 55-64 years in which the risk in women was lower. Detailed data on 
the prevalence of AHT compared to the general-population are shown in table-2.  
 
Table 2. Observed prevalence of AHT in the ASAS-COMOSPA study (Latin America*) compared with the expected 
prevalence in general population and prevalence of Global ASAS-COMOSPA for reference. 
n=number with a diagnosis of arterial hypertension in each gender and age group  
Prevalence (%); LA*, Latin America (Data confined to patients from Colombia and México); **SRR, standardized risk 
ratio (ratio calculated for the age of 25-64 years); NA, not available 
Hypertension defined as a history of hypertension or antihypertensive therapy use or blood pressure ≥140/90 mm Hg 
at the study visit.  
 
The distribution of TB prevalence and risk is presented in table-3. Overall, the observed prevalence 
of TB infection in LA patients with SpA in the three countries was 3.3% (95%CI 1.8 to 5.7), which was 
much higher than expected from the general population (0.32%) in these three LA countries and 
also higher than the prevalence data of the global ASAS-COMOSPA-study (2.5%) (95%CI 2.0 to 3.0). 







Gender Age n  (%) Prevalence (%)   n        (%) 
Men 
≤24 0 0 NA 
- 
 3 2.65  
 25-34 4 12.5 3.6  3.4  49 8.47   
 35-44 2 8.7 7.8  1.1  152 24.4   
 45-54 6 28.5 14.6  1.9  247 43.3   
 55-64 4 57.1 30.9  1.8  240 61.1   
 ≥65 7 70.0 NA -  201 84.1   
 Total 23 22.3 12.9  1.4 (0.9-2.2)  892 34.4   
         
Women 
≤24 0 0  NA -  0 0   
25-34 1 8.3 0.9  9.2  17 7.4   
35-44 2 15.3 3.8  4.0  61 16.8   
45-54 5 41.6 17.0  2.4  132 36.8   
55-64 1 11.1 34.3  0.3  104 45.6   
≥65 1 25.0  NA -  102 68.6  
Total 10 19.6 12.1  1.5 (0.8-2.8)  416 29.8   
          





TB prevalence in LA was lower in men than in women (2.8 vs. 4.2% respectively); in contrast to the 
global study in which the prevalence was higher in men (3.0 vs. 1.6% respectively). Cases of TB in 
LA were observed after the age of 35 and homogeneously distributed among all age groups 
regardless of gender (in total: 7 cases of TB in males and 6 cases in females). Seven of these cases 
were reported in Argentina and six in Colombia. In contrast in the ASAS-COMOSPA-study, TB cases 
were reported as early as at an age of 25 years and were more frequent in men (78 male and 23 
female cases). The average risk of TB was 10.3 times higher in SpA patients than in the general-
population. The risk was more increased in women than in men (18.2 vs. 6.8 respectively) and was 
found in all age categories except in patients ≥65 years in whom the risk declined in both genders.  
 
Table 3. Observed prevalence of TB in the ASAS-COMOSPA study (Latin America*) compared with the 
expected prevalence in general population and prevalence of Global ASAS-COMOSPA for reference. 
n= number with a history or current active TB  







SRR (CI 95%) 
Global ASAS-
COMOSPA 
Gender Age groups n (%) Prevalence (%)  n (%)  
Men 
20-24 0 0 0.29 - 0 0 
25-34 0 0 0.21 - 16 2.7 
35-44 2 3.3 0.23 14.3 15 2.4 
45-54 2 4.3 0.40 10.7 18 3.1 
55-64 2 7.4 0.73 10.1 12 3.1 
≥65 1 4.0 1.14 3.5 17 7.1 
Total men 7 2.8 0.41 6.8 (3.2-13.9) 78 3.0 
        
 20-24 0 0  0.22 - 0 0 
Women 
25-34 0 0 0.13 - 1 0.4 
35-44 2 5.6 0.15 37.3 4 1.1 
45-54 1 2.8 0.19 14.7 6 1.7 
55-64 2 7.4 0.37 20.0 11 4.8 




6 4.2 0.23 18.2 (8.5-40.6) 23 1.6 
        





The malignancies found in SpA patients in men were: prostate-cancer (n=2), skin-cancer (n=2), 
colon-cancer (n=1); and in women: cervix-cancer (n=2), breast-cancer (n=2) and skin-cancer (n=2). 
The majority of cases had been reported in patients ≥50 years of both genders, (7 cases in Argentina, 
3 cases in Colombia and one case in Mexico). The overall prevalence of malignancies observed in 
the three LA countries was 2.8% (95%CI 1.4 to 5.1), which was slightly lower than the prevalence in 
the global ASAS-COMOSPA-study (3.2%, 95%CI 2.6 to 3.8) and not significantly increased in 
comparison to the general-population (2.6%) (p=0.5). The SRR for malignancies was 1.0. There was 
not a significant increase in the prevalence and the risk to develop malignancies in patients with 
SpA compared with the general-population (Table-4). 
 
Table 4. Observed prevalence of all malignancies in the ASAS-COMOSPA study (Latin America) compared with the 
expected prevalence in general population and prevalence of Global ASAS-COMOSPA for reference. 
n=number with a diagnosis of malignancies in each gender and age group. 





General  population 
SRR (CI 95%) 
Global  
ASAS-COMOSPA 
Gender Age groups N (%) Prevalence (%)  n (%) 
Men 20-39 0 0 0.41 - 4 0.3 
 40-44 0 0  0.76 - 2 0.6 
 45-49  0 0 1.29  - 5 1.6 
 50-54 1 5.0 2.39 2.0 8 3.0 
 55-59 1 7.6 4.11  1.8 9 3.9 
 60-64 1 7.1 6.49 1.0 9 5.4 
 65-70 1 8.3 9.28 0.8 13 11.3 
 ≥70 1 7.6 15.17 0.5 27 21.9 
 Total men 5 2.0  2.41 0.8 (0.3-1.9) 77 2.9 
        
Women 
20-39 0 0  0.54 - 6 1.2 
40-44 0 0  1.91 - 3 1.6 
45-49 1 4.3 2.70 1.5 4 2.2 
50-54 2 15.3 3.53  4.3 11 6.0 
55-59 2 13.3 4.49 2.9 6 4.6 
60-64 1 8.3 5.90 1.4 10 10.0 
65-70 0 0 6.98  - 4 4.8 
≥70 0 0 9.57 - 7 10.7 
Total women 6 4.2  2.67 1.5 (0.7-3.4) 51 3.6 
        






The results of this study show that the prevalence and the risk of ATH and TB is increased in patients 
with SpA if compared to the age- and gender-adjusted general-population in LA. Of note, the 
prevalence and the risk to develop malignancies were not significantly increased in SpA patients in 
comparison to the reference population.   
 
Studies assessing the prevalence of AHT in AS patients have yielded different results. These 
discrepancies could be explained by the heterogeneity of study populations investigated 20. A cross-
sectional US analysis 21 of the risk factors of CV disease showed an increased prevalence ratio of 
AHT in AS (1.3 [95%CI 1.1-1.4]) compared with control subjects (27% vs. 22%). Similar rates were 
observed in patients with PsA in this study. In a recent Dutch study a higher prevalence of AHT, 
stratified by age and gender, was observed in AS patients (41%) than in the general population (31%) 
22. Furthermore, a Canadian study has shown that AHT was more common in AS patients (23%) than 
in matched controls without AS (18%) 23. Our results are consistent with these studies, reporting a 
higher AHT prevalence in patients with SpA as compared to a reference population of non-SpA 
individuals. In contrast, a Swedish study did not find a substantial difference between AS patients 
and controls regarding AHT (32% vs 29%, respectively) 24. While chronic inflammation may have had 
a detrimental effect on endothelial function and may have accelerated the progression of 
atherosclerosis, the common use of NSAIDS that we found in the current study (72%) is a more likely 
explanation for the increased prevalence of AHT. 
 
A significantly higher prevalence and risk of developing TB in patients with SpA was found. Genetic 
factors favouring disease reactivation from latent TB or progression of the infection in addition to 





explain this finding. Additionally, it is also challenging to relate the increased prevalence of TB to 
the immune disturbances caused by the disease itself, which may also contribute to the risk of 
developing TB. This increased rate of TB has been observed previously in the early stages of disease 
in patients with SpA 6 and was expected to be present also in patients with longer disease duration 
(and longer exposure to inflammation), as in the current study (mean disease duration of 7.0 years). 
Previous studies in anti-TNF naïve RA patients have shown an increased risk of developing TB 
(ranging from a 4-fold to a 7-fold increase) compared with the general population 10, suggesting that 
uncontrolled and chronic inflammation predisposes to TB.     
 
Although some studies have reported that the overall prevalence of TB is lower in women, plausible 
reasons to explain such a differential effect remain obscure. Factors such as differences in the 
progression from infection to clinically manifest disease, differences in immune system responsivity 
and biological differences in disease presentation may be part of the explanation 25.  Although the 
incidence of TB in LA has declined in the last two decades, the region is still considered an endemic 
area for TB, mainly due to the presence of social factors that predispose to the disease 26. In general, 
these factors increase the exposure to TB-bacilli.  
 
The risk of developing a malignancy was not significantly increased in SpA patients in comparison 
to the general population. This finding is consistent with previous studies reporting that the overall 
risk of malignancies was not significantly higher in AS and PsA patients, including those treated with 
DMARDs or TNF-inhibitors 27. While malignancies are not rare in patients with AS, there is not a 






Previous studies in LA have assessed the prevalence rates of comorbid conditions, especially in RA. 
A systematic literature review evaluating CV risk factors in RA patients 28 found that AHT was the 
most common finding in almost all studies performed in the region, with an overall prevalence of 
28% (range 11.2% to 80.6%). In our study, we found a prevalence of AHT in SpA patients of 25.3%, 
in the three LA countries, which was higher than expected from the general population but still 
lower than the prevalence reported in RA. This finding is consistent with the data observed in AS 
patients, in whom CV risk factors are less manifest than in RA8. Regarding TB data in LA, a recent 
prospective Brazilian study of patients with chronic inflammatory arthritis including AS, RA and PsA 
has suggested that patients who start TNF blockers have a significantly higher rate of active TB than 
healthy-controls (87 vs 36/100,000 person-years) 29.  
 
This study has limitations. First, the sample of patients may not be generalizable to the patient 
population in each country or the whole region. This cohort may not have been fully representative 
of all SpA patients in the participating countries; moreover, the sample was rather small (especially 
for Colombia and Mexico) and limited to those patients that had access to specialized rheumatology 
care in academic centers. In particular, the higher educational status in Mexico and Colombia gives 
rise to the suggestion that the sample that was investigated may not be entirely representative of 
the population of SpA patients in these countries. This should be taken into account when 
interpreting the results. 
 
In addition, the patients in this study were from only three LA countries, namely those that 
participated in the international ASAS-COMOSPA-study. Moreover, data of Argentina with regard to 
AHT was not included in the analyses for comparison to general population and calculation of SRR. 





ethnic and demographic differences; therefore, the AHT data was analysed only for two countries. 
This limits the ability to extrapolate findings to the whole region. Second, the prevalence of some 
comorbidities might have been underestimated, because patients may have been unable to 
participate due to clinically relevant conditions. On the other hand, comorbidities might have been 
overestimated because of investigation bias: SpA patients with comorbidities that are known to be 
associated with the disease may be overrepresented in this sample. Finally, it is important to 
mention an additional source of potential bias in relation to TB-case-ascertainment: While the 
global TB report had been based on comprehensive data reported at the national level according to 
guidelines by the World Health Organization, in the COMOSPA study cases of TB had been 
ascertained by the patients and subsequent medical record review. These data do not necessarily 
yield the same results. 
 
In conclusion, LA patients with SpA have an increased risk of developing AHT and TB compared with 
the general-population. These findings illustrate the need for optimal detection and monitoring of 
these conditions in SpA patients, and have implications for rheumatologist’s health assessments, 
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Objective To compare the frequency and severity of periodontitis in SpA-patients with healthy-
control individuals, through the evaluation of clinical, serological and microbiological periodontal 
condition. 
Methods Patients with a diagnosis of SpA (n=78) and bDMARD-naive fulfilling the ASAS 
classification criteria as well as 156 healthy-controls matched for age/gender, were included. Two 
trained and calibrated periodontologists performed the periodontal clinical assessment. The 
presence of periodontitis and its severity were determined according to the criteria established by 
the Center for Disease Control and Prevention-American Academy of Periodontology (CDC-AAP). 
The clinical periodontal variables, IgG1/IgG2 antibodies against P. gingivalis and periodontopathic 
bacterial identification, were also established. Comparisons of periodontal characteristics between 
the SpA-patients and the control-group were performed using univariable analyses. A logistic 
regression analyses was performed to calculate the odds ratio (95% CI) for diagnosis of periodontitis 
in SpA-patients and matched-controls.       
Results A diagnosis of periodontitis was established in 56% in SpA patients vs. 69% of healthy-
controls (p=0.01). Severe periodontitis was found in 3% vs 12% in SpA vs healthy-controls 
respectively (p=0.01).  There was no significant increase of frequency of any periodontal variable, 
IgG1/IgG2 antibodies against P. gingivalis or the presence of periodontopathic bacteria between 
SpA patients and control-group. Periodontitis was not positively associated with a diagnosis of SpA 
(OR: 0.57 95% CI 0.32-1.00, p=0.05) in the logistic regression analyses.  
Conclusions We found a lower rather than a higher frequency and severity of periodontitis in SpA 
patients in comparison to healthy-control individuals. Our findings suggest that there is no positive 









Spondyloarthritis (SpA) is a chronic rheumatic disease presenting with axial (axSpA) and peripheral 
(pSpA) manifestations 1. This condition that is characterized by inflammation of the spine and 
peripheral joints has been associated with other inflammatory diseases such as uveitis, psoriasis 
and inflammatory bowel disease 2, 3. Chronic periodontitis is a common worldwide and chronic 
inflammatory condition characterized by progressive destruction of periodontal ligament and 
alveolar bone 4.  
 
Results from studies point towards a potential relationship between periodontitis and systemic 
rheumatic diseases, in particular rheumatoid arthritis (RA) 5. Studies have found that the presence 
of RA has been associated with an increased prevalence of periodontitis and also with a significant 
inflammatory periodontal involvement in early-disease 6, 7. Periodontitis has been considered as a 
condition that influences the risk of developing RA in first-degree relatives 8. Moreover, important 
mechanisms that characterize the pathogenesis of RA are also involved in the pathogenesis of 
periodontitis 9. Many studies have suggested that extra-articular citrullination is an immunological 
event that may occur in periodontal tissue under inflammatory conditions 10. Following this 
reasoning, the citrullination and the induction of anti-citrullinated peptide-antibodies (ACPAs) has 
emerged as a biochemical-process that may initiate the cascade of events leading to inflammation 
in RA 11.  
 
Knowledge of the existence of an epidemiological association between SpA and periodontitis may 
fuel pathophysiological thinking about SpA and if established, have clinical implications. Currently, 
it is unclear whether SpA patients have a higher frequency of periodontitis and data in the literature 
reporting a possible association is limited. Therefore, the aim of the present study was to compare 
the frequency and severity of periodontitis in SpA-patients with age/gender matched healthy-








Consecutive adult patients with a diagnosis of SpA (n=78) and fulfilling ASAS classification-criteria 
12, 13 attending a rheumatology outpatient-clinic in an academic-center for routine care in Colombia 
were selected. A control group of 156 individuals from the general population (between 18-65 
years) matched for gender and age (maximum difference of one year) were enrolled. Healthy 
individual volunteers were selected from the same hospital or geographical area. All controls were 
specifically questioned and were excluded from this study if they reported a history of 
rheumatologic diseases.  Exclusion criteria for cases and controls were use of antibiotics during the 
last 3-months and a history of periodontal or orthodontic therapy. All individuals completed a 
specific questionnaire addressing medical history, demographics, body mass index (BMI), and 
smoking. Information related to current and previous treatment was collected. Disease activity in 
patients with SpA was assessed using the Ankylosing Spondylitis Disease Activity Score (ASDAS) for 
CRP 14.  As TNF-alpha has an important role in the pathogenesis of periodontitis and TNF blockers 
have been considered as a factor that may influence the periodontal condition, all SpA patients 
included in this study were bDMARD-naive. The institutional ethics-committees approved the study 
and study subjects provided written informed-consent. 
 
Periodontal assessment 
Two trained and calibrated periodontologists with intrareader and interreader agreement ≥0.9 with 
the standard, performed the periodontal clinical-assessment 15. Periodontologists were blinded to 
the group category of the individuals (patients or controls) at the time of evaluation. Each patients 
and/or control was examined by one of both periodontologist, and each periodontologist assessed 
about half of the patients and controls. Using a North-Carolina® probe (Hu-Friedy PCPUNC-15), a 
full-mouth examination at six-sites on each permanent tooth was performed. The periodontal 
variables assessed were as follows: clinical attachment loss (CAL), pocket probing depth (PD), 




The presence of periodontitis and its severity were defined according to the criteria established by 
the Center for Disease Control and Prevention-American Academy of Periodontology (CDC-AAP) 16. 
According to these criteria, the definitions were based on measures of CAL and PD at the four 
interproximal sites per tooth. Periodontitis was defined as ≥2 interproximal sites with CAL ≥4 mm 
or ≥2 interproximal sites with PD ≥5 mm (not on same tooth). Severe periodontitis was defined as 
≥2 interproximal sites with CAL ≥6 mm (not on same tooth) or ≥1 interproximal sites with probing 
depth ≥5 mm. 
 
Laboratory testing 
The protocol employed for the detection of IgG1/IgG2 antibodies against Porphyromonas gingivalis 
(P. gingivalis) has been previously standardized 7. To detect these antibodies an indirect ELISA was 
performed in-house in 96-well plates. Each well was coated with 5 mg of a sonicated preparation 
of whole P. gingivalis ATCC33277 and W83 strains. For bacterial identification the following 
procedure was performed: after removing supragingival plaque with curettes and previous relative 
isolation with cotton rolls, a tip of sterile paper (caliber 40-NewStetic) was placed in the gingival 
sulcus for 20 seconds in 6 of the deepest sites of each patient. The paper tips of each site were 
placed in a sterile tube and processed for bacterial by quantitative polymerase chain reaction 17. 
The results for plaque samples were projected on the standard curve generated with P. gingivalis 
(ATCC 33277), T. denticola (ATCC 35405) and T. forsythia (ATCC 43037) and transformed to Log10. 
 
Statistical analysis  
Descriptive analyses were used to calculate means (SD) for continuous data and percentages for 
categorical data. The frequencies of periodontitis, severity, periodontal variables, IgG1/IgG2 
antibodies against P. gingivalis and bacterial identification were established. Comparisons of 
periodontal characteristics between SpA patients and control individuals were performed using 
univariable analyses. For variables with a normal distribution, parametric t tests were used. For 
variables with a non-normal distribution, differences between cases and controls were compared 
by McNemar test for categorical variables or Wilcoxon signed test for continuous variables. A 
logistic regression analysis was performed with the diagnosis of periodontitis as a dependent 
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variable. Odds ratios with 95% confidence interval were calculated. All analyses were performed at 
a significance level of 5%. The statistical package STATA version 12 was used.   
 
RESULTS 
Demographics and clinical characteristics 
In total 78 patients in the SpA group and 156 individuals in the healthy control group were matched 
by age and gender. In the SpA group the mean age was 39.6 (11), 60% were men and the distribution 
by subtypes was as follows: ankylosing spondylitis (AS) (n=25), non-radiographic axSpA (nr-axSpA) 
(n=41) and pSpA (n=12). Patients with SpA had a mean disease duration of 5.0 (7.1) years and ASDAS 
of 2.7 (0.8).  Of the SpA patients 45% was HLA-B27-positive. In total, 82% of SpA patients were 
receiving nonsteroidal anti-inflammatory drugs (NSAIDS) and 49% were receiving sulphasalazine. 
 
Periodontal clinical assessment 
In the group of SpA, 56% had a diagnosis of periodontitis, compared with 69% in the control group 
(p=0.01), according to the parameters of the CDC/AAP. In total, 2.6% had severe periodontitis in 
contrast to 12.2% in the control group (p=0.01). CAL was less severe in SpA (1.9 (0.6) mm) as 
compared to controls 2.4 (0.8) mm (p=<0.001). Additionally, the total in-mouth insertion level was 
found to be lower in SpA patients 2.4 (0.5) mm in comparison to their matched controls 2.9 (0.8) 
mm (p=<0.001). Results are presented in table 1. In the logistic regression analyses, periodontitis 
was not positively but negatively associated with SpA (OR=0.57, CI 95% [0.32–1.00], p=0.05).  
 
Antibodies and bacterial identification   
There was no significant increase of frequency with regard to IgG1 / IgG2 antibodies against P. 
gingivalis and the presence of periodontopathic bacteria between SpA patients and healthy 





Table 1 Characteristics and periodontal variables in patients with 








Age (years) 39.6 (11.0)  39.5 (11.1)  ⱡ  
Male gender N (%) 47 (60.3)  94 (60.3)  ⱡ  
Smoking (currently) N (%) 11 (14.1)  14 (9.0)  0.14 
Obesity (BMI ≥30) N (%) 6 (7.6)  16 (10.2)  0.43 
Periodontitis (positive)* N (%)                                 44 (56.4)  108 (69.2)  0.01 
Severity of Periodontitis* N (%)         
          Any 34 (43.6)  48 (30.8)  0.01 
          Mild 11 (14.1)  20 (12.8)   
          Moderate 31 (39.7)  69 (44.2)   
          Severe 2 (2.6)  19 (12.2)   
Insertion level total mouth (mm) 2.4 (0.5)  2.9 (0.8)  <0.001 
CAL average interproximal (mm) 1.9 (0.6)  2.3 (0.8)  <0.001 
Total pocket depth mouth (mm) 3.3 (1.7)  3.2 (1.9)  0.29 
Plaque Index (%) 0.4 (0.2)  0.5 (0.2)  0.12 
Gingival index (%)  0.3 (0.2)  0.4 (0.5)  0.33 
Number of teeth present 26.1 (4.1)  25.5 (5.4)  0.79 
P. gingivalis (presence) N (%) 23 (29.4)  71 (45.5)  <0.01 
T. denticola (presence) N (%) 13 (16.6)  84 (53.8)  <0.001 
T. forsythia (presence) N (%) 6 (7.6)  75 (48.1)  <0.001 
IgG1 anti P. gingivalis (positive) N (%) 40 (51.2)  80 (51.2)  1 
IgG2 anti P. gingivalis (positive) N (%) 41 (52.5)  74 (47.4)  0.32 
All values given as mean (SD) unless specified;  
ⱡ Age and gender were matching criteria 
*Criteria and severity definition according to the Center for Disease Control and  
Prevention-American Academy of Periodontology (CDC-AAP)  
BMI, body mass index; CAL, clinical attachment loss 
 
DISCUSSION 
The results of this case-control study suggest that –unlike the situation in RA- there is not a positive 
association between SpA and periodontitis in Colombian patients. We even found a lower 
prevalence of periodontitis and less severe periodontitis in comparison to healthy controls. 
Moreover, all periodontal characteristics evaluated including clinical parameters, antibodies anti P. 
gingivalis and bacterial identification were not increased in SpA patients as compared to controls.  
 
Several studies on the association between periodontitis and RA have been published 18. 
Periodontitis has been considered a condition with an increased prevalence in individuals with RA 
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and also has been related to the progression of inflammatory involvement in these patients 19. In 
contrast, in the current study we did not find a relationship between SpA and periodontitis. Patients 
with SpA do not share the same genetic risk factors, female predominance and disease-specific 
autoantibodies such as ACPAs with RA. The citrullination of proteins, which has been suggested the 
“link” behind the association between RA and periodontitis, is a biochemical process that has not 
been found relevant in the pathogenesis of SpA 20. Moreover, the prominent role of HLA-B27 in SpA 
has not been involved in the pathophysiology of periodontitis. To our knowledge there is no data 
evaluating the potential contribution of the allele HLA-B27 in the pathogenesis of periodontitis.  
 
A potential association between SpA and periodontitis has been investigated in previous studies. In 
a study including 51 patients with psoriatic arthritis the frequency of periodontitis was similar and 
statistically not different compared with control subjects (41 vs. 38% respectively) (p=0.90) 21. In 
contrast, a case-control study in Germany including 48 patients with AS reported a significantly 
higher risk of periodontal disease compared to controls (OR= 5.4, CI 95% 1.4-22.0) 22. However, the 
case definition of periodontal disease in this study was based on a clinical measure (CAL≥3mm) 
instead of a clinical diagnosis or established criteria. Moreover, a study using administrative claims 
data sourced from the National Health Insurance program in Taiwan reported that AS patients are 
1.8 times more likely than controls to have a previous diagnosis of chronic periodontitis (OR= 1.8, 
CI 95% 1.7-1.9).  However, all the cases of periodontitis analyzed in this study were sourced from 
an administrative database, which may be less accurate than a clinical diagnosis made by 
periodontologists. Recently, a systematic review and meta-analysis including six case-control 
studies reported a prevalence rate of periodontitis that ranged from 38% to 88% in AS patients vs. 
a range from 26% to 71% in controls 23. Although the authors report an increasing risk of AS 
associated with periodontitis (OR=1.85, CI 95% 1.7-1.9), the potential confounding factors, high 
level of heterogeneity and methodological weakness among the few eligible studies may limit the 
interpretation of the results. Moreover, the different case-definitions of periodontitis used in these 
studies may have influenced the prevalence of periodontitis and hamper to establish clear 




Our study has strengths and weaknesses. The main limitations are the cross-sectional design, which 
complicates the generation of causal inferences. Moreover, there is a limited sample size. However, 
without a signal at all in any of the periodontitis parameters, it is unlikely that a larger sample size 
would yield fundamentally different results. Among the strengths of this study are the 
comprehensive periodontal assessment that had been performed, in addition to the serological and 
microbiological investigations for the comparison of cases and controls. To our knowledge this is 
one of the first studies assessing the periodontal condition in the full spectrum of SpA including 
axSpA and pSpA patients.  Moreover, all SpA patients included were not previously or currently 
exposed to TNF blockers. TNF-alpha has an important role in the pathogenesis of periodontitis. 
Medications such as TNF blockers have been considered as a factor that may influence the risk of 
periodontitis and even improve the periodontal condition 24. In this study we have avoided such 
potential confounding.  
 
A higher percentage of patients were taking NSAIDs and sulphasalazine and the effect of these 
medications with regard to the modulation of periodontal condition has not been clearly 
established. While multiple studies have investigated the effect of NSAIDs on the periodontal 
condition in terms of reducing gingival inflammation and influencing alveolar bone loss 25, 26, more 
information is needed investigating the role of NSAIDs as modulatory agents of periodontal disease 
progression in patients with SpA 27, 28.  
 
A point of concern may be the high prevalence of periodontitis in the Colombian general 
population. A nation-wide population study led by the Colombian Ministry of Health reporting on 
the oral health status in adults ≥18 years old (ENSAB IV), found a prevalence of periodontitis of 62% 
29. Moreover, a higher percentage of men had periodontitis in comparison to women (67% vs. 58%). 
This national-data are in concordance with the prevalence found in the control-group in the current 
study, taking into account that SpA has a male-predominance and the sample had been matched 
by gender.  This finding implies that Colombia may have a higher prevalence of periodontal disease 
than other countries such as the United States (47%) 30 or Germany (51%) 31. In this context, 
country-specific differences with regard to the prevalence of periodontitis in the general 
population, should be considered in the interpretation and the external validity of our findings.   
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In conclusion we have found a lower- rather than a higher frequency and severity of periodontitis 
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Validation and reliability of translation of the ASAS Health Index in a Spanish speaking 
population with spondyloarthritis 
 














Objective To validate a Spanish-language translation of the ASAS Heath-Index (ASAS-HI) testing its 
reliability, construct validity and responsiveness in Colombian-patients with spondyloarthritis. 
Methods Translation was done following a forward-backward procedure. Patients fulfilling the 
ASAS criteria for either axial or peripheral-SpA participated. Test-retest reliability was assessed by 
intraclass correlation coefficient (ICC) in patients without treatment changes. In patients who 
required a therapeutic intervention, responsiveness was assessed using the standardized response 
mean (SRM). Construct validity was evaluated by Spearman correlation. Internal consistency 
(Cronbachs-α) and discriminative ability of the ASAS-HI were assessed.  
Results Fifty patients were included: 54% male, mean (SD) age 44.8(13.1), symptom duration 
15.8(9.7) years, BASDAI 4.6(2.2), BASFI 4.7(2.5), ASDAS-CRP 2.2(1.0). AxSpA was established in 44 
patients (AS=30, nr-axSpA=14) and pSpA in 6. The score of the ASAS-HI was 8.2(5.1). The test-retest 
reliability was good with an ICC of 0.84. SRM was 2.58 (1.75-3.37) in 10 patients with any 
intervention and 2.94 (2.13-4.24) for 7 patients starting TNF-blockers. Construct validity showed a 
good correlation between ASAS-HI and pain, BASDAI, BASFI, and ASDAS (r≥0.60). A high internal 
consistency was found with a Cronbachs-α of 0.91. ASAS-HI discriminated well between patients 
with different stages of disease activity (BASDAI and ASDAS). Those with higher disease activity had 
higher ASAS-HI scores. 
Conclusion The Spanish-language translation of the ASAS-HI has proven to be psychometrically 
valid for Colombian-patients with SpA. This version is available to evaluate the state of health and 







The term spondyloarthritis (SpA) is used to describe a disease characterized by axial and entheseal 
inflammation, as well as extra articular manifestations such as uveitis and psoriasis 1. Ankylosing 
spondylitis (AS) is the prototype of SpA and together with non-radiographic axial SpA (nr-axSpA), 
constitutes the subgroup that is termed axial SpA (axSpA). This group of patients differentiates from 
peripheral SpA (pSpA) by the predominance of axial- rather than peripheral manifestations as 
presenting feature 2, 3. Given the variable course of SpA, the evaluation of health and functioning is 
increasingly recognized by health care professionals to be an important outcome when assessing 
the impact of the disease on the patient.  
 
The Assessment of Spondyloarthritis international Society (ASAS) Health Index (HI) has been 
developed to measure functioning and health in patients with SpA aiming to better describe the 
impact of disease in these patients 4. The ASAS-HI is a linear composite measure based on an item 
pool which has been developed and based on the International Classification of Functioning (ICF) 
core set for AS 5. This index forms a unidimensional scale providing a sum score representing a wide 
spectrum of different levels of functioning and contains 17 dichotomous aspects addressing the 
following categories: pain, emotional functions, sleep, sexual functions, mobility, self-care, 
community life and employment. The questions of the questionnaire range from 0 to 17, with a 
lower score indicating a better health status. Recently, the ASAS-HI has been translated and 
adapted cross-culturally into 15 languages worldwide 6.  
 
The English version has proven to be valid and reliable for use in patients with SpA 7. Since validated 
Spanish patient-reported and composite measures do not exist for assessing the broad impact of 
health and functioning in SpA patients, the present study aimed to translate and cross-culturally 
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adapt the English version of the ASAS-HI into Spanish-language spoken in Colombia and to re-assess 
reliability and construct validity for patients with SpA after translation.  
 
METHODS 
Translation and cultural adaptation 
Translation and cross-cultural adaptation of the English version of ASAS-HI was performed 
according to the published recommendations using a standardized operating procedure (forward-
backward procedure) 8. This method consists of the following 5 steps: translation, synthesis of 
translation, back translation, expert committee review and pre-testing in a field test with cognitive 
debriefing. First, three persons (all bilingual) with different profiles or background (including non-
medical), independently performed a forward translation of the instrument from the original 
language (English) to the Spanish-language according to the characteristics of our patients. Back 
translation was then conducted by two independent bilingual native English speakers blinded to 
the English version. The expert committee agreed upon the final wording of the Spanish version, 
who examined semantic, idiomatic, experiential and conceptual issues. All the versions of the 
questionnaire were consolidated to develop a pre-final version for the field test. The final version 
(Appendix 1) was tested with 10 native patients with axSpA (60% AS and 40% nr-axSpA). The 
patients completed the questionnaire in a face to face interview with a physician. Each question 
was discussed with the patient in order to check whether all items had been fully understood and 
whether the patient had problems with wording, relevance, acceptability, incomplete concept 
coverage and comprehensiveness of the translation. Notes were taken about the time to complete 
the questionnaire and whether the patients made comments about specific items when completing 





A sample of patients from a rheumatology outpatient clinic in Colombia were invited to complete 
the ASAS-HI. Adult SpA patients fulfilling the ASAS classification criteria either axial or peripheral 
were eligible for participation. According to the ASAS international validation study 6 a convenient 
sample was obtained: at least 80% of patients with axSpA and a maximum of 20% with pSpA. 
Estimated proportion of axSpA patients were approximately 40% with nr-axSpA and 60% with AS. 
The institutional ethics committee approved the study. Informed consent was obtained from all 
participating patients.  
 
Assessments 
Demographic and clinical information was collected in the first visit (baseline) including age, gender, 
years of formal education, work status, presenting symptoms, extra articular manifestations and 
current results of laboratory test for C-reactive protein (for ASDAS) 9. To assess the different disease 
aspects of health, patients were asked about their disease duration (symptoms duration), current 
medication and completed the patient global assessment (NRS), pain (NRS), spinal pain (NRS), the 
Bath Ankylosing Spondylitis Disease Index (BASDAI) 10, the Bath Ankylosing Spondylitis Functioning 
Index (BASFI) 11, EuroQol five dimensions questionnaire (EQ-5D) 12, Short Form Survey Instrument 
36-Item (SF-36) 13, Hospital Anxiety and Depression Scale (HAD-S) and ASAS-HI.  
 
Reliability 
A subsample of patients with no change in treatment (no change in NSAIDS over last week, no 
change in DMARD or TNF blockers over last 4 weeks) who considered themselves in a stable disease 
state were invited to complete the questionnaire at home after 4-7 days interval to evaluate 




Sensitivity to change 
Patients with clinical disease activity who required an important therapeutic intervention because 
of unacceptable clinical disease activity were invited to complete the questionnaire during a second 
visit 4-24 weeks after the initiation for NSAIDS and 12-24 weeks after the initiation for DMARDS 
(methotrexate, sulfasalazine) or TNF blockers (sensitivity arm).  Baseline assessments including the 
questionnaires and clinical assessments were performed in the clinic. 
 
Statistical analysis 
Reliability was assessed by the test-retest method at 4-7 days interval for patients who considered 
themselves in a stable state. It was measured using the intra-class correlation coefficient (ICC) as 
an estimate of the instrument reproducibility over time -assuming that no modification in health 
conditions had occurred. For testing sensitivity to change, patients were included in the analyses if 
they report improvement on a global change question. Results obtained before and after treatment 
were compared and sensitivity to change was measured using the standardised response mean 
(SRM), which is calculated by dividing the mean score change by the standard deviation (SD) of the 
change.  
 
Construct validity was analysed between ASAS-HI score and several other health outcomes: patient 
global, pain, spinal pain, BASDAI, BASFI, ASDAS, SF-36, EQ-5D and HAD-S using Spearman’s 
correlation coefficient (considered good if ≥0.6). Internal consistency was evaluated by Cronbach’s 




The discriminant ability of the ASAS-HI was assessed between groups differing in overall health -the 
four disease activity states according to the ASDAS score 8 (inactive, moderate, high and very high). 
All statistical tests were two-sided and p values ≤0.05 were considered significant. Statistical 
analyses was done using SPPS (Chicago, Illinois, USA) version 19. 
 
RESULTS 
Translation and cultural adaptation 
No major problems for translation and cross-cultural adaptation were observed. Overall, none of 
the patients had difficulties in answering the ASAS-HI and they felt comfortable with evaluating the 
questionnaire. Results of the cognitive debriefing demonstrated that the translated version of the 
ASAS-HI was properly understood. The mean (SD) time to complete the ASAS-HI was 2.55 (0.9) 
minutes.       
 
Clinimetric properties of the ASAS-HI 
Subjects 
Fifty patients agreed to participate and completed the questionnaire. The diagnosis was axSpA in 
44 patients: AS (n=30) nr-axSpA (n=14) and pSpA in 6 patients. Of these patients, 18 participated in 
the test-retest reliability study arm and 10 participated in the sensitivity to change study arm. The 
characteristics of the population are presented in table 1.  Fifty four percent of the patients were 
male, mean age of 44.8 (13.1) years and symptom duration of 15.8 (9.7) years. The mean scores for 
clinical assessments were: BASDAI 4.6 (2.2), BASFI 4.7 (2.5) and ASDAS-CRP 2.2 (1.0). The total score 





Table 1 Demographic and clinical features of SpA patients (n=50) 








Male N (%) 17 (57) 6 (43) 4 (67) 27 (54) 
Age (years) 46.0 (14.8) 45.1 (9.0) 38.5 (11.3) 44.8 (13.1) 
University education N (%) 12 (40) 4 (29) 0 (0) 16 (32) 
Symptom duration (years) 18.9 (9.5) 12.7 (8.6) 7.8 (6.5) 15.8 (9.7) 
Patient global (0-10 NRS) 4.8 (2.7) 5.0 (2.3) 4.0 (2.6) 4.8 (2.5) 
Pain (0-10 NRS) 4.8 (3.2) 2.6 (2.0) 0.5 (0.7) 4.0 (3.1) 
Spinal pain (0-10 NRS) 4.6 (3.3) 3.0 (1.7) 0.5 (0.7) 3.9 (3.1) 
BASDAI 4.7 (2.4) 4.5 (1.7) 4.0 (2.9) 4.6 (2.2) 
BASFI 5.1 (2.6) 4.3 (1.7) 3.6 (3.0) 4.7 (2.5) 
ASDAS 2.3 (1.1) 2.2 (0.7) 2.0 (1.2) 2.2 (1.0) 
ASAS-HI 8.4 (5.5) 8.4 (3.2) 6.6 (7.4) 8.2 (5.1) 
All values given as mean±SD unless specified 
SpA, spondyloarthritis; AS, ankylosing spondylitis; NRS, numerical rating scale; BASDAI, Bath ankylosing spondylitis 
activity disease indez; BASFI, Bath ankylosing spondylitis functional index; ASDAS, Ankylosing Spondylitis Disease 
Activity Score, ASAS HI, The Assessment of Spondyloarthritis international Society Health Index 
 
Test-retest Reliability  
The mean (SD) baseline ASAS-HI was 8.9 (5.0) and the second ASAS-HI was 7.4 (5.4) in the 18 
patients in the reliability arm. The ICC was good 0.84 (95% CI 0.71 to 0.93, p<0.001).  
 
Sensitivity to change 
Ten patients required change of treatment: 7 patients started a TNF blocker, 2 patients started 
NSAIDS and 1 patient a DMARD. The SRM was 2.58 (1.75 to 3.37) for all patients requiring 
modification of treatment (n=10). For those patients in which the intervention was starting a TNF 
blocker (n=7) the SRM was higher: 2.94 (2.13 to 4.24) than those starting a NSAID or DMARD (n=3), 






Construct validity  
The ASAS-HI had good correlation with the following disease specific clinical parameters: patient 
global (r=0.58), spinal pain (r=0.59), pain, BASDAI, BASFI, ASDAS, and HAD-S (r=0.60-0.70) and the 
highest correlations with EQ-5D and SF-36 (r>0.70). The correlations of ASAS-HI with age and 
symptom duration were weak. Results are presented in table 2.  
 
Table 2 Correlation coefficient (95% IC) between ASAS-HI score and  
clinical characteristics (n=50) 
 Spearman correlation coefficient  
Characteristics ASAS-HI score P value 
Age -0.007     0.96 
Symptom duration  -0.11  0.43 
Patient global (0-10 NRS) 0.58  < 0.0001 
Pain (0-10 NRS)  0.61  <0.0001 
Spinal pain (0-10 NRS) 0.59  <0.0001 
BASDAI 0.66  <0.0001 
BASFI 0.62  <0.0001 
ASDAS 0.65  <0.0001 
EQ-5D 0.75  <0.0001 
SF-36 (physical component) 0.72  <0.0001 
SF-36 (mental component) 0.74  <0.0001 
HAD-S Anxiety 0.65  <0.0001 
HAD-S Depression 0.69  <0.0001 
ASAS HI, The Assessment of Spondyloarthritis international Society Health Index; 
BASDAI, Bath ankylosing spondylitis activity disease index; BASFI, Bath ankylosing 
spondylitis functional index; ASDAS, Ankylosing Spondylitis Disease Activity Score; NRS, 
numerical rating scale; EQ-5D, EuroQol five dimensions questionnarie; SF-36, Short 
form Health Survey 36 items; HAD-S, Hospital Anxiety and Depression Scale. 
 
Internal consistency 




Discriminative ability  
Finally, the ASAS-HI was discriminative between the four health states of the ASDAS score (inactive, 
moderate, high and very high disease activity). The groups with greater disease activity had higher 
mean ASAS HI scores than those with lower disease activity. Results are given in table 3.  
 
Table 3 Discriminant ability of ASAS-HI stratified by disease activity 









ASAS-HI  2.5 ± 5.9 5.9 ± 3.0 9.4 ± 3.9 13.6 ± 2.0 
BASDAI  1.2 ± 0.5 3.6 ± 1.0 5.8 ± 1.5 6.8 ± 0.4 
All values given as mean±SD 
ASAS HI, The Assessment of Spondyloarthritis international Society Health Index; BASDAI, Bath 
ankylosing spondylitis activity disease index; ASDAS, Ankylosing Spondylitis Disease Activity Score. 
 
DISCUSSION 
The translated and culturally adapted version of the ASAS-HI reported in the current study 
maintains all the properties of the original English-language version of the questionnaire. The 
procedure implemented to translate the instrument followed a standardized operating procedure 
according to the recommendations published by Beaton 8. Further we tested several aspects of its 
validity, relevance and comprehensibility among patients with SpA. Therefore, the health status 
and functioning in Spanish-speaking patients with SpA may be properly assessed with the translated 
version of the original ASAS-HI.   
 
The psychometric properties of this Spanish-language version of the ASAS-HI were consistent with 
the results found in the original study 6, and also with the study of the validity of the Korean-
language translation15. The reliability of the adapted version showed a good test-retest reliability 
107 
 
(ICC >0.8) and a high internal consistency (Cronbach-α >0.9). The ASAS-HI was sensitive to pick up 
changes after starting a new pharmacological treatment. The SRM was higher than those seen in 
the original description of the instrument, a fact that could be explained by the higher baseline 
values on the instrument that could imply a higher probability of significant changes after effective 
treatment. Regarding construct validity, the translated version had good correlation (>0.6) with 
several clinical parameters used currently to assess function, disease activity and quality of life in 
patients with SpA. In addition, the instrument was discriminative regarding different thresholds of 
disease activity.   
 
Some limitations need to be considered. First, when evaluating test-retest reliability, no external 
and objective measure was included to assess stability of the health condition. However, it is 
accepted that a seven-day period in a chronic disease is an appropriate interval to avoid a significant 
variability in health, on the one side, and avoid too much recall bias on the other side. Second, the 
Spanish-language version of the ASAS-HI validated in the current study is validated for the 
Colombian population. Regarding other Spanish-speaking populations, the use of this version may 
require additional cross-cultural adaptation and validation mainly due to linguistic variations and 
cultural differences.  Two additional Spanish-versions of the ASAS-HI are available (Mexico and 
Spain) and were elaborated independently during the international validation project. The 
differences with these translated tools are restricted to a few changes in wording. For instance, the 
original English version asks about problems using toilet facilities. The word “toilet” was translated 
using different Spanish words in each country. In the same way, “exhausted” was translated using 
three different words having the same meaning. Similar findings were observed with the translation 
of the following words: “car”, “hair” and “flat ground”. Although these semantic differences may 
reflect the transcultural adaptation of the instrument in each country, the underlying concept to 
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assess functioning remains the same. Third, although the 9 items of the Environmental Factors sets 
related to the ASAS-HI were additionally translated and evaluated in the field test, the 
questionnaire was not included in the current study.  
 
Our study contributes to SpA assessment by providing a reliable and valid cross-culturally adapted 
Spanish-speaking version of the ASAS-HI that is sensitive to change. This adapted instrument may 
be complementary to previous tools validated in Spanish-language and currently implemented in 
trials and clinical practice to assess patients with SpA 16, 17.  
 
In conclusion, the Spanish ASAS-HI version represent a relevant and comprehensive patient-based 
instrument for evaluating the state of health and functioning in Colombian patients with SpA. This 
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Objective: To investigate how well the ASAS/OMERACT core set and response criteria for ankylosing 
spondylitis (AS) have been implemented in randomized controlled trials (RCTs) testing 
pharmacological and non-pharmacological interventions. 
Methods: A systematic literature search was performed up to June 2013 looking for RCTs in patients 
with axial SpA (AS and non-radiographic axial SpA). The assessed domains and instruments 
belonging to the core sets for disease controlling anti-rheumatic therapy (DC-ART) and symptom 
modifying anti-rheumatic drugs (SMARD) were extracted. Results were reported separately for 
those trials published until 2 years after the publication of the core set (1 April 2001; ‘control trials’), 
and those trials published at least two years after the publication date (‘implementation trials’). 
Results: One hundred twenty three articles from 99 RCTs were included in the analysis, comparing 
48 ‘control trials’ and 51 ‘implementation trials’. Regarding DC-ART core set, the following domains 
were significantly more frequently assessed in the ‘implementation group’ in comparison to the 
‘control group’, ‘physical function’ (100% vs 41.7%; p0.001), ‘peripheral joints/entheses’ (100% vs 
33.3%; p0.001) and ‘fatigue’ (100% vs 0%; p0.001). Three instruments were significantly more 
used in the ‘implementation group’: BASFI (100% vs 8.3%; p=0.001), CRP (92.3% vs 58.3%; p=0.01) 
and BASMI (53.8% vs 0%; p=0.001). 
Regarding SMARD core set domains, physical function (92% vs 23%; p0.001) and fatigue (84% vs 
17%; p0.001), as well as the instruments BASFI (88% vs 14%; p0.001) and BASMI (52% vs 0%; 
p0.001), increased significantly in the ‘implementation group’. Twenty percent of trials from the 
‘implementation group’ but none from the ‘control group’ included all domains of the core-set. 
Conclusion: In conclusion, this study provides evidence for the implementation of the 
ASAS/OMERACT core-set in RCTs of both DC-ART and SMARD. This applies to the use of the domains 




Spondyloarthritis (SpA) refers to a group of chronic inflammatory rheumatic disorders, and 
ankylosing spondylitis (AS) is considered the prototype of this group 1. In an attempt to bring more 
homogeneity in outcome assessment in AS and facilitate the conduct of clinical trials, the 
Assessment of SpondyloArthritis international Society (ASAS) has selected core sets of variables to 
include as standardized end points in clinical trials and clinical practice. These core sets have been 
endorsed by the Outcome Measures in Rheumatology Clinical Trials (OMERACT) group 2.  
 
ASAS has defined three scenarios for core-sets: 1) disease controlling anti-rheumatic therapy (DC-
ART); 2) symptom modifying anti-rheumatic drugs (SMARD) and physical therapy; and 3) clinical 
record keeping.  The domains selected for all three core-sets include ‘physical function’, ‘pain’, 
‘spinal mobility’, ‘stiffness’, ‘fatigue’ and ‘patient’s global assessment’. The core-sets DC-ART and 
clinical record keeping further include ‘peripheral joints/entheses’ and ‘acute phase reactants’ and 
the core-set for DC-ART includes ‘radiographs of the spine’. In addition, specific instruments to 
assess each of these domains were chosen 3. 
 
It has been postulated that the definition of core-sets and the choice of appropriate instruments, 
which were effective in 1999 4, have importantly facilitated the development and successful 
registration of new treatments in AS. However, it is difficult to prove if, and to what extent, the 
core-sets have contributed to this. An indirect indication for the value of core-sets in the 
development of new treatments could be the demonstration that the usage of domains and 
instruments has measurably increased after the description of the core-sets (implementation). In 
rheumatoid arthritis, a recent study found evidence of uptake of the core set 5. 
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However, the implementation of the ASAS/OMERACT core-sets has so far not been evaluated. The 
main purpose of this systematic literature review, therefore, is to analyze and compare the usage 
of domains and instruments of the core-sets before and after the publication of the original article 
(April 1999). In addition, we checked the implementation of ASAS response criteria. 
 
METHODS 
In order to ensure the transparent and complete reporting of this systematic review, the PRISMA 
statement was used as guidance 6. The research question was structured according the PICOT 
strategy: population, interventions, control group, outcome and study types. The ‘population’ was 
defined as trials in patients with a diagnosis of AS or SpA. The ‘intervention group’ was defined as 
trials with pharmacological and non-pharmacological interventions published after April 2001 (the 
date was defined two years after the publication date to ensure that there was sufficient time to 
include the core set measures in RCTs). The ‘control group’ was defined as trials with 
pharmacological and non-pharmacological interventions published before April 2001. ‘Outcome’ 
was defined as the domains and instruments in the core-sets for SMARD/physical therapy and DC-
ART. ‘Study type’ was confined to RCTs.  
 
A systematic literature search was performed in PUBMED Medline and EMBASE electronic library 
databases to identify target studies using a comprehensive search strategy. The search was updated 







Articles in English, French, German, Dutch, Portuguese or Spanish were selected for analysis. All of 
the descriptions and synonyms for AS and SpA were used in the search terms, in order to identify 
all relevant studies. Details of search strategy terms for identification of studies can be found online 
as a supplementary web-Appendix. 
 
Study Selection 
Two authors (WB, VN) independently screened each title and abstract in order to select the articles 
for inclusion in the review. They determined the eligibility of each article according to predefined 
selection criteria. The main inclusion criterion was:  RCT’s including patients with AS and/or SpA. 
Since axial SpA constitutes a new term that includes patients with predominantly axial symptoms 
of SpA, studies with non-radiographic axial SpA patients were also included. Since some studies 
have included not only axial SpA patients but also patients with other rheumatic conditions, we 
have selected those studies in which at least an arbitrary 80% of the patients were axial SpA 
patients.     
 
If title and abstract provided insufficient information, the full article text was obtained and 
reviewed. Reasons to exclude studies were: the sole report of outcomes not included in the ASAS 
core-set; and the impossibility to obtain a full text. Disagreement between the reviewers regarding 
inclusion of the articles studies was resolved by consensus. The references of all included papers 







The same two authors extracted the data from the included studies independently according to a 
predetermined and standardised outcome review matrix. Differences regarding data extraction 
were resolved by re-review and consensus discussion by the two primary reviewers. General data 
extracted included information about first-author, publication year, study start date and end date, 
study duration, interventions, total number of patients randomized and number of AS/SpA patients 
and primary outcome. The presence/absence of reported domains collected were: ‘physical 
function’, ‘pain’, ‘spinal mobility’, ‘stiffness’, ‘fatigue’, ‘patient global assessment’, ‘peripheral 
joints/entheses’, ‘acute phase reactants’ and ‘spine radiographs’. 
 
All different instruments and outcomes described in each study were extracted and included in the 
analysis. The instruments that were noted for each domain were those included in the ASAS core 
set, as well as additional instruments that were considered belonging to the same domains.  Table1 
describes the domains and the instruments according to the ASAS/OMERACT core-set, as they were 
published originally in 1999 and with a minor modification to add additional instruments in 2009 2, 
3.  
 
If the composite measure BASDAI (Bath ankylosing spondylitis disease activity index) was reported, 
we considered the following domains also as performed: fatigue, pain, stiffness and peripheral 
joint/entheses, even though these were not separately reported. If the BASMI (Bath ankylosing 
spondylitis metrology index) was reported,  we considered the domain spinal mobility as well as 
the instruments lateral spinal flexion, tragus-to-wall distance, modified Schober’s test, 
Intermalleolar distance and cervical rotation also as performed, regardless of whether they were 
separately reported. Additionally, measures for the evaluation of treatment response were 
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extracted; including the response criteria ASAS20 7, ASAS40 8, ASAS5/6 and BASDAI50, and the 
disease state ASAS partial remission.  
 
Table 1 Assessment of SpondyloArthritis international Society (ASAS)/Outcome in Rheumatology 
(OMERACT) core set for symptom modifying anti-rheumatic drugs (SMARD), disease-controlling 
anti-rheumatic treatments (DC-ART) and specific instruments for each domain.  
 
Domains Instruments 
van der Heijde, 1999 
Instruments 




BASFI [9] or Dougados Functional 
Index (DFI) [10] 
 
BASFI 
Pain VAS, last week, spine, at night, due 
to AS 
VAS, last week, spine, due to AS 
NRS/VAS (last week/spine/night/due to 
AS) 
NRS/VAS (last week/spine/due to AS) 
Spinal mobility                     Chest expansion [11], modified 
Schober test [12], occiput to wall 
distance 
Chest expansion, modified Schober, 
occiput to wall, cervical rotation,  
(lateral spinal flexion or BASMI) [13] 
Spinal stiffness                     Duration of morning stiffness,  
spine, last week 
NRS/VAS (duration of morning stiffness, 
spine, last week) 
Patient global VAS last week NRS/VAS (global disease activity last 
week) 
Peripheral joint, entheses Number of swollen joints (44-joint 
count), no instrument for entheses 
Number of swollen joints (44 joint 
count) MASES [14], San Francisco or 
Berlin 
Acute phase reactants ESR CRP or ESR 
Radiograph spine AP/lat lumbar and lat cervical spine 
and X-pelvis (SI and hips) 
mSASSS [15] on lateral lumbar spine / 
lateral cervical spine  
Fatigue No preferred instrument   Fatigue question BASDAI [16] 
 
BASDAI, Bath Ankylosing Spondylitis Functional Index; NRS, Numerical Rating Scale; VAS, Visual Analogue Scale; 
BASMI, Bath Ankylosing Spondylitis Metrology Index; MASES, Maastricht Ankylosing Spondylitis Enthesis Score; CRP, 
C-reactive protein; ESR, Erythrocyte Sedimentation Rate; mSASSS, modified Stoke Ankylosing Spondylitis Spinal 




First, all information retrieved from multiple articles but belonging to the same RCT was combined 
and considered as one RCT for the analysis. The datasets were analyzed to compare the use of the 




Since the ASAS-endorsed response criteria were published in 2001 (ASAS20 and ASAS partial 
remission) and in 2004 (ASAS40 and ASAS 5/6), only studies published two years after those dates 
were included in the assessment of these criteria, in order to give time for the implementation. The 
number of trials assessing all domains of the core set was analysed for interventions and control 
group, in trials evaluating interventions with DMARDSs, biologics and glucocorticoids as well as 
trials with other types of interventions including NSAIDS. In order to illustrate the evolution of the 
representation of domains and instruments overtime two figures were constructed.  
 
For descriptive purposes, results were presented as means and standard deviations or medians for 
continuous variables, and as frequencies (percentages) for categorical variables. The Student t-test 
for independent samples and Chi-square tests (and Fisher test if necessary) were used to compare 
continuous and dichotomous variables between implementation and control groups, respectively. 
Statistical analysis was done using SPSS software version 18.0. 
 
RESULTS 
Results of the search 
The search strategy generated a total of 566 articles. Of these, 127 articles reporting the results of 
99 clinical trials fulfilled the eligibility criteria. Reasons to exclude studies are mentioned in the flow 
chart. An important reason to exclude was that the clinical outcomes we were interested in were 


























Characteristics of the RCTs 
Forty-eight of the 99 RCTs fell in the group of ‘control trials’ and 51 in the group of ‘implementation 
trials’. A total of 12,261 patients, 94% (n=11,497) of those having a diagnosis of AS and 2% (n= 251) 
having a diagnosis of non-radiographic axial SpA, were included in the trials. The remaining patients 
(4%, n=513) had a diagnosis of another rheumatic condition such as another SpA subtype (psoriatic 
arthritis, undifferentiated SpA and reactive arthritis), rheumatoid arthritis and osteoarthritis.  
 
Records identified through database searching  
Medline (n =369) Embase (n = 197) 
(n =566) 



































Records screened after duplicates removed   
(n =441) 
Records excluded by 
abstract  
(n =271) 
Full-text articles assessed for 
eligibility  
(n =170) 
Full-text articles excluded  
(n = 48): 
 no clinical outcome (n=15) 
duplicate (n=2)  
no full text available (n=23) 
no RCT (n=2)  
≤80% axial SpA (n=6) 
Articles included in 
qualitative synthesis  




The median number of AS patients per trial was similar (60 versus 61) in the ‘control’ vs the 
‘implementation group’. Median study duration was slightly higher in the ‘control’ group in 
comparison to the ‘implementation’ group (20 vs 16 week). Trials evaluating the efficacy of NSAIDs 
(52% vs 8%; p0.001) and DMARDs (21% vs 6%; p=0.06), were more frequently found in the 
‘control’ group as compared to the ‘implementation’ group. However, trials evaluating biological 
drugs (45% vs 0%; p0.001) and also physical therapy (27% vs 10%; p=0.03), were more frequently 
represented in the ‘implementation’ group as compared to the ‘control’ group. The main 
characteristics of the RCTs in both groups are shown in table 2. 
 
In trials evaluating interventions with DMARDs, biologics and glucocorticoids, 5 out of 26 trials 
(19%) in the ‘implementation group’ but none of the trials in the ‘control group’, included all 
domains of the core-set. In trials with all other types of interventions -including NSAIDS-, a full set 
of domains was used in 8 out of 25 trials (32%) of the ‘implementation group’ and in 1 out of 36 
trials (3%) of the ‘control group’. 
 
Table 2 Characteristics of Randomized Controlled Trials selected for detailed review  
 Control group 
(before April 2001) 
(n = 48)  
Implementation group 
(after April 2001) 
(n= 51) 
 
 mean ± SD median  
Min, Max 
mean ± SD median  
Min, Max 
p value ¶ 
N. patients (n) 117 ± 140 60  
(35-140) 
131 ± 145 61 
(45-185) 
0.7 
N. Axial SpA patients 
(n) 
114 ± 138 60  
(33-134) 
126 ± 145 58 
(45-154) 
0.6 


















  NSAIDs 25 52 4 7.8 < 0.001 
  DMARDs 10 21.3 3 5.9 0.06 
  Biological drugs 0 0 23 45.1 < 0.001 
  Glucocorticoids 2 4.3 0 0 0.2 
  Physical therapy 5 10.6 14 27.5 0.03 
  Balneotherapy 0 0 4 7.8 0.05 
  Miscellaneous* 6 12.8 3 5.9 0.4 
*Miscellaneous interventions: fish oil capsules, pamidronate, levamisole, amitriptilyne, probiotic oral 
therapy, formicarufa, cognitive-behavioural therapy. ¶ p values are for comparison between groups. 
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RCTs evaluating DMARDs, biological drugs or systemic glucocorticoids  
Domains 
The usage of the domains and instruments recommended for the DC-ART scenario is shown in Table 
3. The domains ‘patient global assessment’ was assessed in about 60% of the trials (61% vs 67%; 
p=0.8) in ‘implementation’ and ‘control group’. The domain ‘spine radiograph’ was only assessed in 
the implementation group (23% vs 0%; p=0.07). Three domains were substantially more frequently 
represented in the ‘implementation group’ as compared to the ‘control group’ and were even 
assessed in all trials of the implementation group: ‘physical function’ (100% vs 42%; p0.001), 
‘peripheral joints/entheses’ (100% vs 33%; p0.001) and ‘fatigue’ (100% vs 0%; p0.001). Four 
domains also show a high level of usage in the ‘implementation group’ but were already high in the 
‘control group’: ‘pain’ (100% vs 92%), ‘spinal mobility’ (81% vs 92%), ‘spinal stiffness’ (100% vs 92%) 
and ‘acute phase reactants’ (96% vs 83%). 
 
 Instruments 
A number of instruments had a low usage in the trials of both the ‘implementation group’ and 
‘control group’: ‘pain night’ (42% vs 33%) and ‘joint count’ (42% vs 33%). With respect to the 
instrument ‘joint count’ the number of joints assessed was very different ranging from 22 to 70 
joints. Three instruments were substantially more frequently reported in the ‘implementation’ vs 
the ‘control group’: ‘BASFI’ (100% vs 8%), ‘BASMI’ (54% vs 0%) and ‘CRP’ (92% vs 59%). The domain 
‘pain global’ was frequently used in both groups (100% vs 92%). Concerning ‘radiographic 
progression’, two instruments -‘mSASSS’ and ‘BASRI’- were used, but were only reported in 
‘implementation trials’. The instruments ‘MASES’ and ‘Berlin’, both for the domain ‘peripheral 
joint/entheses’, were evaluated only after 2001. Although the most commonly selected instrument 
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to evaluate ‘physical function’ in the ‘implementation group’ was the ‘BASFI’, in many trials more 
than one instrument was used to evaluate this domain. 
 
Table 3 Implementation of ASAS/OMERACT Core Outcome Set (DC-ART) and specific instruments in 
each domain in trials evaluating interventions with DMARDs, biological drugs or glucocorticoids. 
 DC-ART Control group 
(before 2001) 



















Physical function 5 (41.7) - 26 (100) - < 0.001 
     BASFI 1 (8.3) - 26 (100) -  
     Dougados-FI 4 (33.3) - 1 (3.8) -  
     HAQ 1 (8.3) - 4 (15.4) -  
Pain* 11 (91.7) 11 (91.7) 26 (100) 19 (73.1) 0.3 
     Night 4 (33.3) - 11 (42.3) -  
     Global* 11 (91.7) 11 (91.7) 26 (100) 19 (73.1)  
Spinal mobility** 11 (91.7) 11 (91.7) 21 (80.8) 21 (80.8) 0.4 
     BASMI 0 - 14 (53.8) -  
     Cervical rotation** 2 (16.7) 2 (16.7) 14 (53.8) 4 (15.4)  
     Lateral spinal flexion** 0 0 15 (57.7) 5 (19.2)  
     Schober 7 (58.3) - 8 (30.8) -  
     Modified Schober** 4 (33.3) 4 (33.3) 18 (69.2) 5 (19.2)  
     Intermalleolar distance** 0 0 14 (53.8) 4 (15.4)  
     Tragus to wall distance** 0 0 15 (57.7) 5 (19.2)  
     Occiput to wall distance 4 (33.3) - 7 (26.9) -  
     Chest expansion 10 (83.3) - 12 (46.2) -  
Spinal stiffness* 11 (91.7) 11 (91.7) 26 (100) 15 (57.7) 0.1 
Patient global assessment 8 (66.7) - 16 (61.4) - 0.8 
Peripheral 
Joints/entheses* 
4 (33.3) 4 (33.3) 26 (100) 14 (53.8) < 0.001 
     Joint count 4 (33.3) - 11 (42.3) -  
     MASES 0 - 4 (15.4) -  
     Berlin Index 0 - 1 (3.8) -  
Acute phase reactants 10 (83.3) - 25 (96.2) - 0.2 
     CRP 7 (58.3) - 24 (92.3) -  
     ESR 10 (83.3) - 13 (50.0) -  
Spine radiograph 0 - 6 (23.1) - 0.07 
     mSASSS 0 - 4 (15.4) -  
     BASRI 0 - 3 (11.5) -  
Fatigue* 0 0 26 (100) 7 (26.9) < 0.001 
¶ p values are for comparison between assessment performed in control and implementation group 
1Intervention in these studies: DMARDs (10) and glucocorticoids (2) 
2Intervention in these studies: DMARDs (3) and biological drugs (23) 
* If BASDAI was reported, we considered the following domains (fatigue, pain, stiffness and peripheral 
joint/entheses) were performed although these were not separately reported.** If BASMI was reported, we 
considered this domain (spinal mobility) and the following instruments (lateral spinal flexion, tragus to wall distance, 
modified Schober, Intermalleolar distance and cervical rotation) were performed although these were not 
separately reported. DC-ART, disease controlling anti-rheumatic therapy; BASFI, Bath Ankylosing Spondylitis 
Functional Index; BASMI, linear definition of the Bath Ankylosing Spondylitis Metrology Index, CRP, C-reactive 
protein; ESR, erythrocyte sedimentation rate; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; MASES, 
Maastricht Ankylosing Spondylitis Enthesis; BASRI, Bath Ankylosing Spondylitis Radiology Index 
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RCTs evaluating NSAIDs, physical therapy and miscellaneous interventions  
Domains and instruments 
These results on implementation in RCTs evaluating NSAIDs, physical therapy and miscellaneous 
interventions are shown in table 4. The domain ‘patient’s global assessment’ showed a low 
percentage of usage in the ‘implementation group’, and even lower than in the trials of the ‘control 
group’ (36% vs 51%). ‘Physical function’ and ‘fatigue’ were significantly more frequently used in the 
trials of the ‘implementation group’ as compared to the ‘control group’: (92% vs 23%; p=<0.001 and 
84% vs 17%; p<0.001), respectively, whereas the domain ‘pain’ had a high representation in the 
trials of both groups (96% vs 89%). 
 
Regarding the instruments, we found that ‘Dougados FI’ and ‘night pain’ had a rather low 
representation in trials of both groups: (8% vs 9%) and (20% vs 44%) respectively. The 
representation of ‘BASFI’ (88% vs 14%) and ‘BASMI’ (52% vs 0%), however, improved significantly 













Table 4 Implementation of ASAS/OMERACT Core Outcome Set (SMARD) and specific 
instruments in each domain in trials evaluating interventions other than DMARD, biological 
drugs or glucocorticoids 
SMARD Control group 
(before 2001) 









 (n, %) 
Reported 
separately 










Physical function 8 (22.9) - 23 (92.0) - < 0.001 
     BASFI 5 (14.3) - 22 (88.0) -  
     Dougados-FI 3 (8.6) - 2 (8.0) -  
     HAQ 3 (8.6) - 0 -  
Pain* 32 (88.8) 30 (85.7) 24 (96.0) 15 (60.0) 0.3 
     Night 16 (44.4) - 5 (20.0) -  
     Global* 30 (85.8) 29 (82.9) 24 (96.0) 15 (60.0)  
Spinal mobility** 28 (77.7) 27 (77.1) 23 (92.0) 23 (92.0) 0.1 
     BASMI             0 - 13 (52.0) -  
     Cervical rotation** 2 (5.7) 2 (5.7) 13 (52.0) 6 (24.0)  
     Lateral spinal flexion** 5 (14.3) 5 (14.3) 14 (56.0) 7 (28.0)  
     Schober 21 (58.3) - 5 (20.0) -  
     Modified Schober** 3 (8.6) 3 (8.6) 18 (72.0) 10 (40.0)  
     Intermalleolar distance** 2 (5.7) 2 (5.7) 14 (56.0) 7 (28.0)  
     Tragus to wall distance** 1 (2.9) 1 (2.9) 14 (56.0) 6 (24.0)  
     Occiput to wall distance 12 (34.3) - 7 (28.0) -  
     Chest expansion 24 (66.6) - 17 (68.0) -  
Spinal stiffness* 25 (71.5) 24 (68.6) 22 (88.0) 11 (50.0) 0.1 
Patient global assessment 18 (51.4) - 9 (36.0) - 0.2 
Fatigue* 6 (17.1) 4 (11.4) 21 (84.0) 6 (24.0) 0.001 
¶ p values are for comparison between assessment performed in control and implementation group 
1Intervention in these studies: NSAIDs (25), physical therapy (5) and miscellaneous (6) 
2Intervention in these studies: NSAIDs (4), physical therapy (13), balneotherapy (5) and miscellaneous 
(3) 
* If BASDAI was reported, we considered the following domains (fatigue, pain, stiffness and peripheral 
joint/enthuses) was performed although it was not separately reported. 
** If BASMI was reported, we considered this domain (spinal mobility) and the following instruments 
(lateral spinal flexion, tragus to wall distance, modified Schober, Intermalleolar distance and cervical 





Evolution of usage of domains and instruments over time 
In order to illustrate the evolution of the representation of domains and instruments, figures 2a 
and 2b were constructed. An increasing usage of domains and instruments was found over time. 
Looking at the results, the increased usage was primarily attributable to the advent of RCTs testing 
biological drugs shortly after the year 2001. We did not find an important increase in usage of 
domains over time in RCTs with NSAIDs, DMARDs or miscellaneous interventions, but the number 
of ASAS core-set instruments per RCT increased not only in biological drugs RCTs but also in RCTs 
with miscellaneous interventions. 
 
Figure 2a Dot plot illustrating the number of ASAS core set domains per trial according to 
the date of publication and type of intervention. Miscellaneous interventions in this 
context, include physical therapy and other kind of treatments. Glucocorticoids are 















Figure 2b Dot-plot illustrating the number of ASAS core-set instruments per trial according 
to the date of publication and type of intervention. Miscellaneous interventions in this 
context, include physical therapy and other kind of treatments. Glucocorticoids are 




ASAS-endorsed response criteria and other outcomes 
Since the ASAS response criteria and partial remission criteria were published in 2001 (ASAS 20 and 
ASAS partial remission criteria) and in 2004 (ASAS 40 and ASAS 5/6), only studies published two 
years after those dates (n=45 and n=33 respectively) were included in the analyses (in this context 
only trials from the ‘implementation group’ were investigated). ASAS 20 response criteria were 
reported in 40% of the trials (18 out of 45 trials), ASAS 40 in 45% (15 out of 33) of the trials, ASAS 
5/6 in 30% (10 out of 33) and ASAS partial remission in 22% (10 out of 45).  The reported 
percentages for each response criteria are different mainly due to the publication date and the 
implementation time. The number of trials reporting the response criteria are not the same -e.g. 
ASAS 20 (45 trials) and ASAS 40 (30 trials).   
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In Table 5, the ASAS response criteria are presented according to type of intervention. A high level 
of usage was found in trials with biological drugs (ASAS 20 (73%), ASAS 40 (93%), ASAS partial 
remission (53%) and ASAS 5/6 (60%). BASDAI 50 was reported as response measure only in 
implementation trials (25%; n= 13). 
 
Table 5 Usage of ASAS response criteria according to trial intervention 
Intervention (%) ASAS 20* ASAS partial 
remission* 
ASAS 40** ASAS 5/6** 




























Trials included since 2004* and 2006** according to publication date of respective response criteria 
 
DISCUSSION 
This study confirms the implementation of the ASAS/OMERACT core set in randomized clinical trials 
after the original publication. A substantial improvement in the utilization of ASAS-endorsed 
domains and to a lesser extent of ASAS-endorsed instruments overtime is evident. Additionally, an 
increasing number of RCTs has reported a full or nearly full spectrum of ASAS-core domains, which 
was observed across all interventions. Overall, the utilization of the DC-ART core set is very good 
and better than that of the SMARD core set. 
 
The domains ‘physical function’, ‘peripheral joint/entheses’, ‘fatigue’ and ‘spine radiograph’ 
improved substantially over time. ´Physical function’ is considered an important outcome measure 
for the evaluation of disease evolution and additionally is a domain relevant to the patient, and is 
reported by a high proportion of studies (92%). Moreover, ‘BASFI’ included by ASAS as the preferred 
instrument, is far more often used as a method for the evaluation of ‘physical function’ (88%). 
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A similar trend of utilization was observed with the domain ‘spine radiograph’. With the expectation 
that there would be a positive effect by treatment on structural damage, it stimulated the inclusion 
of this domain in more recent trials. The domains ‘acute phase reactants’, ‘pain’, ‘spinal mobility’ 
and ‘spinal stiffness’ were already frequently used before the publication of the core sets and this 
has remained unchanged. The only domain that did not show an increased usage over time is 
‘patient global assessment’ (61% for DC-ART and 36% for SMARD core set).  
 
Regarding the specific instruments to measure each domain there is clearly more homogeneity, as 
non-endorsed instruments that were used frequently in the past are not used so often anymore 
after the introduction of the core set. Nevertheless, the overall level of implementation of specific 
instruments still leaves room for further improvement, especially for the SMARD core set. 
 
A remarkable improvement in the usage of domains and instruments is attributable to RCTs with 
biological treatments, intended for drug registration purposes.  These RCTs are usually of very high 
methodological quality, and trial planning teams that were responsible for the choice of primary 
and secondary outcome measures have scrutinized the literature to search for the best set of 
instruments. In this context the ASAS core-set as such, may have contributed to the performance 
of these trials, to a more transparent drug registration process and to a better acceptance of new 
treatments in the field. 
 
The ASAS response and partial remission criteria are intended for use in the evaluation of drug 
treatment. Therefore, it could be expected that the best implementation is seen in trials evaluating 
biological therapies, and this is most obvious with regard to the use of the ASAS40 and ASAS5/6, 
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which were developed to assess relatively better responses, as could be expected to occur in 
efficient drugs such as biological drugs. 
 
As a possible limitation of our analysis is that the time period of two years after the publication as 
a cut-off point between the two groups of trials, is an arbitrary choice and may not be sufficient to 
assess the implementation properly. Indeed we have found that there is a further increase in 
implementation over the years. A strength of this study is that a primary and very comprehensive 
search of the entire literature was conducted specifically aiming at the population of interest. 
 
All domains and instruments that have been used in the trials should be reported. Interestingly we 
have found that sometimes domains and instruments were used but not reported separately. For 
example, the domain ‘fatigue’, which is included in the ‘BASDAI’, as well as specific instruments 
included in the BASMI, were not always reported separately. There might be several explanations 
for this. A trivial one is space constraint, but online appendices may resolve this problem. Another 
possibility is that authors only report positive results. Most likely, however, authors may not 
understand the purpose of core sets: Reporting outcomes of a trial in a homogeneous manner, with 
the aim to avoid publication bias and the possibility to compare measures across trials. 
 
In conclusion, this study provides evidence for the utilization of the ASAS/OMERACT core-set in 
RCTs of both DC-ART and SMARD, especially to the use of the domains and to a lesser extent to the 
use of specific instruments. However, there is room for improvement, aiming at reporting the 






Systematic search strategy terms: MEDLINE / EMBASE 
Population: Ankylosing Spondylitis, Spondyloarthritis 
1. Bechterew Disease 
2. Bechterew's Disease  
3. Bechterews Disease  
4. Ankylosing Spondyloarthritis 
5. Ankylosing Spondyloarthritides 
6. Spondyloarthritides, Ankylosing 
7. Spondyloarthritis, Ankylosing 
8. Rheumatoid Spondylitis  
9. Spondylitis, Rheumatoid  
10. Spondylarthritis Ankylopoietica 
11. Ankylosing Spondylarthritis 
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13. Spondylarthritides, Ankylosing 
14. Spondylarthritis, Ankylosing 
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17. Marie Struempell Disease  
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SUMARY AND DISCUSSION 
The studies presented in this thesis cover many aspects related to Spondyloarthritis (SpA) in 
Colombia. The following topics were addressed. First, the analyses and performance of the 
different SpA classification criteria and the factors important in the decision of the rheumatologist 
to order an MRI or HLA-B27 test in the diagnostic work-up of SpA in the context of the clinical 
rheumatology setting. Second, a better insight was obtained with regard to the presence of 
comorbidities and risk factors of patients with SpA. This included also a case-control study to 
evaluate the relationship between periodontitis and SpA. Third, the translation and cross-cultural 
adaptation to Spanish of the ASAS-HI was performed. Finally, the implementation of the domains 
and instruments of the ASAS core set in clinical trials have been evaluated.  
 
In this final chapter, we summarize the main findings of the studies included in this thesis. In 
addition, we will discuss the potential unmet needs in the field of rheumatology in Colombia and 
we propose a research agenda for the upcoming years.   
 
In the first study presented in this thesis, the performance of the various classification criteria 
developed for SpA (ESSG, Amor and ASAS criteria) was tested in a clinical practice cohort of patients 
in Colombia. Patients with a clinical diagnosis of SpA (defined as the reference standard) were 
analysed for the various characteristics included in these classification criteria in chapter 2. In this 
cohort, the ASAS criteria were most sensitive in classifying patients having SpA in comparison to 
ESSG and Amor criteria. Even, the addition of MRI did not substantially increase the classification 
rate of ESSG and Amor criteria. Similar findings with regard to the validity of the ASAS criteria using 
the clinical diagnosis as reference have been reported in the European SPACE cohort 1. In both 
studies, a substantial rate of concordance with regard to the different criteria sets was observed. 
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Considering the marked heterogeneity of axial SpA, this agreement may suggest that the core 
characteristics of SpA are captured by all criteria. Many Colombian rheumatologists establish a 
diagnosis of SpA based on these typical clinical characteristics. However, a bias with regard to 
additional testing of MRI and HLA-B27 was present in this study. These additional tests were mainly 
performed based on clinical indication only, especially in those patients with the highest probability 
of having SpA and in those patients with an uncertain diagnosis. The fact that MRI and HLA-B27 
was not available for all patients may have hampered the comparison of the various criteria sets, 
especially those sets that include one or both tests. Recently, a systematic literature review has 
confirmed the good performance and the validity of the various ASAS SpA criteria as tested against 
the rheumatologist's diagnosis 2. However, in contrast to these validation studies we found a higher 
prevalence of peripheral involvement in Colombian patients. This finding has been consistently 
observed in Latin America for peripheral arthritis as well as for enthesitis 3. Moreover, the 
frequency of HLA-B27 in our cohort was also rather low in contrast to data reported in other 
regions including Europe 4. Differences in the prevalence of HLA-B27 in Colombian population, 
which has a wide geographic and ethnic variation, may explain these findings. Despite these 
differences in prevalence of peripheral symptoms and HLA-B27 in our Colombian dataset, the 
performance of the ASAS SpA criteria is very similar to the published data. 
 
While in clinical practice rheumatologists do not perform MRI or HLA-B27 testing in all patients 
with a suspicion of SpA, they do require these tests in those patients with the highest probability 
of having SpA and in those patients in which clinical symptoms fall short to diagnose but suspicion 
remains. Because of cost, waiting time for MRI and feasibility issues, these tests cannot be 
performed in all patients suspected of having SpA. In chapter 3, using the same data as employed 
in the analyses of the study in chapter 2, we have investigated the patient’s characteristics 
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associated with a clinical decision to order a SI-MRI and/or HLA-B27 testing in the diagnostic work-
up of SpA. We found that the presence of inflammatory back pain (IBP), enthesitis, the number of 
symptoms at presentation and uveitis increased the likelihood of ordering MRI and/or HLA-B27 
testing. These clinical clues are important, because the presence of these manifestations increase 
the pre-test probability of axial SpA and therefore the finding of a positive test may significantly 
contribute to confirming a diagnosis while finding a negative test may help ruling out the disease. 
This is an appropriate manner of increasing the diagnostic efficiency and optimizing the use of 
resources. A recent study from the ESPERANZA cohort has investigated the utility of SpA features 
associated with a higher likelihood of a positive SI-MRI or a positive HLA-B27 in patients with 
chronic back pain 5. They found that IBP according to the ASAS definition plus alternating buttock 
pain or IBP according to Calin criteria plus awakening in the second half of the night predicted the 
presence of finding sacroiliitis on MRI. Our findings assigned IBP as a determinant for ordering SI-
MRI. Together, these studies confirm that the presence of IBP not only evokes an SI-MRI-order, but 
also that this behaviour is rational in that the likelihood of a positive result will increase. Our results 
suggest that clinical reasoning indeed follows the principles of Bayesian theory and that it helps 
rheumatologists to improve efficiency of these tests. Moreover, the efficiency of MRI improves 
when the patients are optimally selected, which relies on training about the appropriate use of SpA 
features 6.  
 
In the study presented in chapter 4 we have performed a comparative study with the general 
population on data from Latin American patients (including Colombia) from the multinational 
Assessment of SpondyloArthritis international Society of COMOrbidities in SpA (ASAS-COMOSPA) 
study 7. The most common comorbidities and risk factors were arterial hypertension (AHT), 
hypercholesterolemia, osteoporosis and gastrointestinal ulcer. The prevalence of AHT (including 
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data from Colombia and Mexico) was increased compared to the general population resulting in a 
standardized risk ratio (SRR) of 1.5 (95% CI 1.0 to 2.1). Many studies have reported a higher 
prevalence of AHT in AS 8, 9, which may reflect the detrimental effects that chronic inflammation 
may have on endothelial function and acceleration of atherosclerosis. The common use of NSAIDS 
in this cohort of patients may also play a role, even though NSAID-use was associated with less 
mortality in a study by Bakland et al 10. In addition, the prevalence of tuberculosis (TB) was 
importantly higher than expected from the general population in LA, resulting in an SRR of 10.3 
(95% CI 6.1 to 17.8). Uncontrolled and chronic inflammation may predispose to TB, in addition to 
the risk that patients receiving immunosuppressive treatments such as corticosteroids 11 and TNF-
inhibitors already have 12. The prevalence and risk of malignancies in comparison to the general 
population was not significantly increased. Although these findings could not be extrapolated to 
the whole region (patients came from the three Latin American countries that participated in the 
ASAS-COMOSPA study), this is one of the first efforts to evaluate comorbidities associated to SpA 
in Latin America. Our findings described in chapter 4 may have implications for daily clinical 
practice with regard to rheumatologist’s health assessments, prevention and treatment planning. 
 
While clinical studies have pointed towards a relationship between chronic periodontitis and 
rheumatoid arthritis 13, it was unclear if SpA patients have a higher frequency of periodontitis. A 
case-control study evaluating the clinical, serological and microbiological periodontal condition in 
a group of patients with SpA is described in chapter 5. We did not find a positive association 
between SpA and periodontitis and we found even a lower prevalence of periodontitis and less 
severe periodontitis in comparison to matched-healthy controls. The explanation of these findings 
is unclear, however, from a physiopathological point of view, it is obvious that the citrullination 14 
of proteins is a biochemical process that likely is not relevant in the pathogenesis of SpA. 
150 
 
The ASAS Health Index has been developed as a composite index based on the International 
Classification of Functioning (ICF) to measure the impact of SpA on patients’ lives 15. The translation 
and cross-cultural adaptation of the English version of ASAS-HI was performed and presented in 
chapter 6 using a standardized operating procedure in Colombian patients with SpA 16. The adapted 
version of the ASAS-HI maintained the good psychometric properties of the original English-
language version of the questionnaire in terms of reliability, sensitivity to change, construct validity 
and discriminative capacity regarding thresholds of disease activity. This validated ASAS-HI in 
Spanish-speaking patients with SpA may be used in clinical practice and research studies. This 
instrument is complementary to other validated tools that assess disease activity, physical function 
and quality of life in Spanish-language, thus completing the toolkit for the assessment of Colombian 
patients with SpA 17 18. 
 
The definition of core sets and the choice of appropriate instruments are relevant in order to 
incorporate important elements from both the patient’s and the physician’s perspective in clinical 
research.  This is particularly important when considering AS and SpA with regard to treatment 
comparisons and when considering which measures and outcomes to report in clinical trials 19. In 
order to evaluate the implementation of the ASAS/OMERACT core sets 20, a systematic literature 
review has been performed to analyse and compare the usage of domains, instruments and ASAS 
response criteria.  The findings are presented in chapter 7 and confirm the implementation of the 
core set in randomized clinical trials after the original publication of the core set in 1999. Overall, 
the utilization of the disease controlling anti-rheumatic therapy (DC-ART) core set was better than 
that of the symptom modifying anti-rheumatic drugs SMARD core set. With respect to the ASAS 
response criteria, as expected, the best implementation was seen evaluating biological therapies. 
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However, there is still room for improvement, aiming at reporting the complete core set and its 
instruments.  
 
Implications of this thesis and future perspectives  
The studies described in this thesis cover relevant aspects of the landscape of Spondyloarthritis in 
Colombia in terms of the performance of classification criteria, the behaviour of rheumatologists 
considering additional testing, as well as comorbidities and risk factors and assessment of health 
status. In a field in which clinical research has been dominated by Europe, this thesis may improves 
the body of knowledge of a condition that has not been properly investigated in Colombia.  
 
The confirmation of the validity of the ASAS SpA classification criteria in a South American 
population supports the good performance of these criteria when tested against the 
rheumatologist´s diagnosis. It also supports the inclusion of patients fulfilling these criteria in 
research studies, ensuring that the patient population is comparable to other regions of the world. 
This may bring research efforts in Colombia at a higher level.   For clinical practice, the appropriate 
selection of additional testing in patients suspected of having SpA based on clinical clues is relevant. 
This pre-selection of patients based on pure clinical reasoning, may help to optimize the 
distribution of health resources and avoid increasing costs of diagnostic tests. This is relevant, 
especially in case of limited resources, which is still the reality in all Latin American countries. We 
strongly believe, that clinical decision making based on Bayesian principles, rather than using 
classification criteria inappropriately, will lead to an improvement of quality of care in clinical 
practice. A monitoring strategy of patients with SpA focusing on treating or avoiding comorbidities 
that we have established here as relevant, may guide rheumatologists to optimize treatment in 
their SpA patients. Moreover, the availability of an adapted version of the ASAS-HI will lead to 
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further exploring the health status and functioning of Colombian patients with SpA. Equally 
important, we have demonstrated that there is no relationship between SpA and periodontitis. 
This finding may not necessarily have clinical implications will help in providing a better 
understanding of the pathophysiology of SpA, since it contrasts with that of RA in terms of the 
importance of citrullination.  
 
Still, we may face many challenges and unmet needs that will require to be addressed in order to 
better understand the burden and the severity of SpA in Colombia and similarly in Latin America. 
National epidemiological studies including representative samples across the countries, may give 
better insight into the prevalence of SpA that of HLA-B27 in our population. The implementation 
and validation of early referral strategies may improve the identification of patients in primary 
care. This type of interventions may help to reduce the time of delay of the diagnosis, which has 
not been estimated yet. With regard to evaluating the contribution of MRI to establishing a 
diagnosis, extensive training is warranted in collaboration with radiologists.  
 
Future improvements of knowledge will lead to increased awareness and earlier diagnosis of SpA. 
Collaborative efforts aiming at promoting clinical and basic research in patients with SpA will 
provide a platform that consolidates this area of research in Latin America. In this regard, the 
design and implementation of a registry for collecting information by a standardized protocol will 
contribute to this purpose.  
 
In summary, in this thesis we have presented and discussed many topics in relation to the field of 
spondyloarthritis in Colombia. Definite progress has been made, but we have to keep moving so 




1  Van den Berg R, de Hooge M, van Gaalen F (2013) Percentage of patients with spondyloarthritis in patients referred 
because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught 
Early (SPACE) cohort. Rheumatology 2:1492–9 
2  Sepriano A, Rubio R, Ramiro S, et al. Performance of the ASAS classification criteria for axial and peripheral 
spondyloarthritis: a systematic literature review and meta-analysis. Ann Rheum Dis 2017;76:886-890 
3  Carneiro S, Bortoluzzo AB, Gonçalves CR et al. Effect of enthesitis on 1505 Brazilian patients with spondyloarthritis. 
J Rheumatol 2013;40:1719–25 
4  Khan MA. HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 1995;7:263–9 
5  Navarro-Compán V, de Miguel E, van der Heijde D et al. Sponyloarthritis features forecasting the presence of HLA-
B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a 
cross-sectional study in the ESPeranza Cohort. Arthritis Res Ther 2015; 17: 265-271 
6  Vossen MH, den Broeder AA, Hendriks-Roelofs F, et al. Improvement in deployment of MRI of the sacroiliac joints 
in patients suspected for spondyloarthritis using a targeted intervention: a case study. Rheumatology (Oxford) 
2013;52:933-8 
7  Moltó A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in 
spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis. 2015 Oct 21. 
pii: annrheumdis-2015-208174 
8  Han C, Robinson DW, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, 
psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72 
9  Haroon NN, Paterson JM, Inman RD, et al. Patients With Ankylosing Spondylitis Have Increased Cardiovascular and 
Cerebrovascular Mortality A Population-Based Study. Ann Intern Med 2015;163:409-16 
10  Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann 
Rheum Dis 2011;70:1921-5 
11  Cisneros JR, Murray KM. Corticosteroids in tuberculosis. Ann Pharmacother 1996;30: 1298–303 
12  Keane J. Tumor necrosis factor blockers and reactivation of latent tuberculosis. Clin Infect Dis 2004;39:300–302 
13  de Pablo, P, Chapple IL, Buckley CD, et al. Periodontitis in systemic rheumatic diseases. Nat Rev Rheumatol 
2009;5:218–224 
14  van Gaalen F, Ioan-Facsinay A, Huizinga TW, Toes RE. The devil in the details: the emerging role of anticitrulline 
autoimmunity in rheumatoid arthritis. J Immunol 2005;175:5575–5580 
15  Kiltz U, van der Heijde D, Boonen A, et al. The ASAS Health Index (ASAS HI) - a new tool to assess the health status 
of patients with spondyloarthritis. Clin Exp Rheumatol 2014;32:S-105-8 
16  Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-
report measures. Spine. 2000;25:3186-91 
17  Cardiel MH, Londoño JD, Gutiérrez E, et al. Translation, cross-cultural adaptation, and validation of the Bath 
Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) and the Dougados Functional Index (DFI) in a Spanish speaking population with spondyloarthropathies. 
Clin Exp Rheumatol 2003;21:451-8 
18  Ariza-Ariza R, Hernández-Cruz B, Navarro-Sarabia F. Physical function and health-related quality of life of Spanish 
patients with ankylosing spondylitis. Arthritis Rheum 2003;49:483-7 
19  Kirkham JJ, Boers M, Tugwell P et al. Outcome measures in rheumatoid arthritis randomised trials over the last 50 
years. Trials 2013;14:324 
20  van der Heijde D, Bellamy N, Calin A et al. Preliminary core sets for endpoints in ankylosing spondylitis. J Rheumatol 
1997;24:2225–9 































































SAMENVATTING EN DISCUSSIE 
 
Dit proefschrift gaat over de ziekte spondyloarthritis (SpA), in het bijzonder in het Zuid-
Amerikaanse land Colombia. SpA is een chronische reumatische ziekte waarbij ontsteking van 
de bekkengewrichten (de SI-gewrichten), de wervelkolom en de perifere gewrichten (zoals 
knieën, enkels) kan optreden. Tegenwoordig wordt de ziekte onderverdeeld in axiale SpA 
(axSpA) (met name klachten als gevolg van ontsteking van de bekkengewrichten en de 
wervelkolom) en perifere SpA (pSpA) (met name klachten als gevolg van ontstekingen in- of 
rond de perifere gewrichten). Vrijwel alle patiënten met SpA hebben last van pijn en stijfheid 
in rug en/of gewrichten. Een scala aan andere manifestaties kan optreden bij axSpA en pSpA, 
zoals chronische darmontsteking, oogontsteking (uveitis) of psoriasis (huidziekte). De oorzaak 
van SpA is onbekend, maar SpA is deels erfelijk bepaald via het gen dat is genaamd HLA-B271. 
De ontsteking van de SI-gewrichten en de wervelkolom kan zichtbaar worden gemaakt op een 
zogenaamde MRI-scan2. Het bepalen van HLA-B27 in het bloed en het beoordelen van een 
MRI-scan van de SI-gewrichten zijn tegenwoordig dan ook hoekstenen van de diagnostiek van 
SpA.  Er bestaan zogenaamde classificatiecriteria voor axSpA en pSpA, die de ziekte en al haar 
manifestaties beschrijven.  De meest recente criteria zijn de ASAS3-criteria uit 2009. Met 
nadruk zij gesteld dat deze criteria niet dienen om de diagnose SpA te stellen, maar veeleer 
om patiënten met SpA in wetenschappelijk onderzoek op te nemen.  
 
In dit proefschrift is onderzocht of deze ASAS-classificatiecriteria ook ‘goed werken’ bij 
patiënten met de diagnose SpA in  Colombia. Dat was niet op voorhand zeker, omdat de 
diagnose SpA wereldwijd verschillend wordt gesteld. Dit heeft te maken met de opvattingen 
van reumatologen over de ziekte SpA, met de technische mogelijkheden die reumatologen 
hebben om een diagnose te stellen (niet iedereen heeft bijvoorbeeld de mogelijkheid om een 
MRI te vervaardigen, of om op HLA-B27 te testen) en met de mate van toegankelijkheid van 
reumatologische zorg (kosten, aantal reumatologen).  
 
In hoofdstuk 2 is een groep patiënten beschreven die volgens de Colombiaanse reumatologen 
SpA hebben (diagnose).  Er is gekeken in welke mate deze SpA-patiënten voldeden aan de 
diverse classificatiecriteria. De voornoemde ASAS-criteria bleken meer patiënten met de 
diagnose SpA op te pikken (waren sensitiever) dan de oudere ESSG4- en Amor5 
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classificatiecriteria (die van vóór het MRI tijdperk zijn). Zelfs als MRI werd toegevoegd als 
criterium aan de ESSG en Amor criteria bleken deze toch niet even goed te zijn als de ASAS-
criteria.  Twee opmerkelijke zaken werden gevonden. Ten eerste maakten Colombiaanse 
reumatologen (waarschijnlijke gedwongen uit kostenoverwegingen) spaarzaam gebruik van 
HLA-B27-test en MRI-scan. Zij deden dit alleen bij gerede twijfel over de diagnose SpA, maar 
niet standaard bij alle patiënten. Ten tweede bleek dat een verhoudingsgewijs groot deel van 
de SpA-patiënten in Colombia perifere SpA had. In Europa zien we juist meer axiale SpA. Dit is 
een bekend gegeven in landen in Latijns-Amerika, dat ook in andere studies werd gevonden. 
 
In hoofdstuk 3 is nader onderzocht bij welke patiënten met SpA HLA-B27 en MRI werd 
aangevraagd.  Het bleek dat vooral bij patiënten met voor SpA typische rugpijnklachten (de 
zogenaamde inflammatoire rugpijn) MRI en HLA-B27 werden aangevraagd, maar verder ook 
bij patiënten met de voor SpA kenmerkende oogontsteking (uveitis anterior) en bij hen die 
meerdere symptomen van SpA hadden.  Feitelijk betekent dit dat Colombiaanse 
reumatologen op doelmatige wijze gebruik maken van beperkte (dure) diagnostische 
hulpmiddelen, hetgeen de kosten van de zorg voor patiënt en samenleving in belangrijke mate 
beperkt.  
 
In hoofdstuk 4 wordt een onderzoek beschreven naar het vóórkomen van andere ziekten (co-
morbiditeiten) bij patiënten met SpA in Latijns-Amerika, namelijk Colombia, Mexico en 
Argentinië. Hiertoe werd gebruik gemaakt van Latijns-Amerikaanse data uit het wereldwijde 
ASAS-COMOSPA6 onderzoek, waarbij co-morbiditeiten bij SpA zijn gemeten.  Door te 
vergelijken met bevolkingsgegevens uit Colombia en Mexico werd aannemelijk gemaakt dat 
met name hoge bloeddruk frequent optreedt bij SpA patiënten in deze landen. Mogelijk komt 
dit door chronische ontsteking die van invloed is op de vaatwand en op het ontwikkelen van 
atherosclerose. Maar het kan ook zijn dat de onstekingsremmers die gebruikt worden bij SpA 
(de zogenaamde NSAIDs7) een  bloeddruk verhogend effect hebben. Voorts werd gevonden 
dat SpA patiënten in Latijns-Amerika vaker dan verwacht lijden aan de infectieziekte 
tuberculose. Dit kan het gevolg zijn van de chronische ontsteking die de afweer onderdrukt, 
of wellicht door afweer-onderdrukkende medicijnen (prednison, TNF-blokkers8). 
Kwaadaardige ziekten kwamen daarentegen niet vaker voor bij SpA- patiënten.  De resultaten 
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van dit onderzoek geven de reumatologen in Zuid-Amerika een handvat om patiënten met 
SpA beter en gerichter te monitoren.  
 
In hoofdstuk 5 wordt een geheel andere weg ingeslagen. Periodontitis is een bacteriële 
ontsteking van de weefsels rondom de tanden. Periodontitis kan leiden tot chronische 
aantasting van het kaakbot en verlies van tanden en kiezen. Maar tegenwoordig wordt ook 
gedacht dat periodontitis het ontstaan van reumatische ziekten (en hart- en vaatziekten) kan 
bevorderen. Voor de ziekte reumatoïde artritis (RA) is dit aannemelijk gemaakt. De ziekte SpA 
heeft enkele overeenkomsten met RA (naast vele verschillen) en we kennen de oorzaak van 
SpA niet. De hypothese die ten grondslag lag aan het onderzoek beschreven in hoofdstuk 5 
was dat er een samenhang bestaat tussen SpA en periodontitis. Om die hypothese te toetsen 
werden Colombiaanse patiënten met SpA uitgebreid periodontologisch onderzocht, en 
werden de bevindingen vergeleken met die van Colombianen zonder SpA. Hoewel 
periodontitis zeer frequent werd gevonden in de Colombiaanse bevolking  werd er absoluut 
geen samenhang gevonden tussen periodontitis en SpA, zodat aannemelijk kon worden 
gemaakt dat –althans in Colombia – periodontitis géén risicofactor voor het ontstaan van SpA 
is, dit in tegenstelling tot RA, waar die samenhang overigens bescheiden is.   
 
In hoofdstuk 6 werd vervolgens het proces beschreven van de vertaling van de Engelstalige 
ASAS-Health Index, een vragenlijst om het algemeen functioneren van SpA- patiënten te 
meten, naar het in Colombia gebruikelijke Spaans. Zo’n vertaling lijkt op het eerste gezicht een 
eenvoudige procedure maar dat is het niet. Immers, de betekenis van verschillende woorden 
en uitdrukkingen zijn sterk cultureel bepaald, en niet één-op-één vanuit het Engels naar het 
Spaans te vertalen zonder dat de precieze betekenis van de woorden verloren gaat.  Voor 
dergelijke ‘transculturele adaptaties’ van vragenlijsten is een gestandaardiseerd proces 
ontwikkeld, dat werd doorlopen om een voor Colombia gevalideerde vertaling van de ASAS-
Health Index te verkrijgen.  
 
In Hoofdstuk 7, tenslotte, worden de resultaten beschreven van een systematisch 
literatuuronderzoek naar het gebruik van zogenaamde ‘core-set variabelen’ in trials bij 
patiënten met SpA.  Core-set variabelen zijn variabelen die door de experts van ASAS en 
OMERACT9 zijn aangemerkt als een minimum om de uitkomst van wetenschappelijk 
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onderzoek bij patiënten met SpA te meten. Deze core-set werd in 1999 vastgesteld, en is nog 
steeds actueel. Voor dit literatuuronderzoek waren wij vooral benieuwd of de core-set 
variabelen ook daadwerkelijk vaker werden gemeten en gerapporteerd  ná 1999 dan vóór 
1999. Dit is belangrijk omdat uniformiteit van metingen bijdraagt aan onderlinge 
vergelijkbaarheid van onderzoeksresultaten. Wij konden inderdaad aantonen dat het meten 
en rapporteren van core-set variabelen na 1999 beduidend was verbeterd, met name bij de 
grote trials met biologische geneesmiddelen na 2002. Er is echter nog steeds ruimte voor een 
betere implementatie van de core-set. 
 
Nawoord 
De ziekte SpA is tot dusver weinig onderzocht in Colombia en andere landen in Latijns 
Amerika. Het is zeer waarschijnlijk dat deze aandoening, die zich bij voorkeur manifesteert op 
jongvolwassen leeftijd, een grote impact heeft op patiënten en samenleving. Door een 
achterstand in kennis bij gezondheidswerkers op het gebied van de diagnose en behandeling 
van SpA, door een gebrekkige fysieke en financiële toegankelijkheid tot de gezondheidszorg, 
en waarschijnlijk ook door een tekort aan ervaren reumatologen, is die impact van de ziekte 
in landen als Colombia wellicht groter dan in ontwikkelde landen. Dit proefschrift zou er aan 
kunnen bijdragen dat er in landen als Colombia meer aandacht ontstaat voor herkenning van 
SpA, voor de voordelen van vroegdiagnostiek en voor optimale behandeling. Hiertoe is het 
van groot belang dat gestructureerd wetenschappelijk patiëntgebonden onderzoek wordt 
geïnitieerd. Mede onder invloed van het onderzoek verricht in de context van dit proefschrift, 




1. HLA-B27: Human Leucocyte Antigen B27, de belangrijkste erfelijke factor die geassocieerd 
is met de ziekte SpA en kan worden gemeten in het bloed van patiënten verdacht voor SpA. 
2. MRI-scan: Magnetic Resonance Imaging-scan, een vorm van beeldvormend onderzoek 
waarbij ontsteking en beschadiging van beenmerg en bot kan worden opgespoord bij 
patiënten verdacht van SpA. 
3. ASAS: Assessment in SpondyloArthritis international Society. ASAS is een wereldwijde 
organisatie van klinische wetenschappers op het gebied van de ziekte SpA.  
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4. ESSG: European Spondylarthropathy Study Group. De groep die de eerste 
classificatiecriteria voor SpA heeft ontwikkeld (1999) 
5. Amor: Naar de Franse reumatoloog Bernard Amor die een alternatieve set van 
classificatiecriteria heeft ontwikkeld. 
6. COMOSPA: Comorbidities in Spondyloarthritis, een patiëntonderzoek van ASAS. 
7. NSAIDs: Non Steroidal Anti-Inflammatory Drugs: Ontstekingsremmers met een pijnstillend 
effect, toegepast bij reumatische aandoeningen. 
8. TNF-blokkers: Tumor Necrosis Factor-blokkerende geneesmiddelen. Biologische 
geneesmiddelen die het effect van dit ontstekingseiwit remmen en worden toepast bij 
reumatische ontstekingsziekten 
9. OMERACT: Outcome Measures in Rheumatology Clinical Trials. OMERACT is een 
wereldwijde organisatie van onderzoekers op het gebied van het meten van de uitkomst van 
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